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ABSTRACT: CC chemokine receptors 2 (CCR2) and 5 (CCR5) are involved in many inflammatory diseases; however, most
CCR2 and CCR5 clinical candidates have been unsuccessful. (Pre)clinical evidence suggests that dual CCR2/CCR5 inhibition
might be more effective in the treatment of such multifactorial diseases. In this regard, the highly conserved intracellular binding
site in chemokine receptors provides a new avenue for the design of multitarget ligands. In this study, we synthesized and
evaluated the biological activity of a series of triazolopyrimidinone derivatives in CCR2 and CCR5. Radioligand binding assays
first showed that they bind to the intracellular site of CCR2, and in combination with functional assays on CCR5, we explored
structure−affinity/activity relationships in both receptors. Although most compounds were CCR2-selective, 39 and 43 inhibited
β-arrestin recruitment in CCR5 with high potency. Moreover, these compounds displayed an insurmountable mechanism of
inhibition in both receptors, which holds promise for improved efficacy in inflammatory diseases.
■ INTRODUCTION
CC chemokine receptors 2 (CCR2) and 5 (CCR5) are two
membrane-bound G protein-coupled receptors (GPCRs),
which belong to the subfamily of chemokine receptors.
Chemokine receptors are widely expressed in leukocytes, and
thus, they regulate different homeostatic and inflammatory
leukocyte functions upon interaction with their endogenous
chemokines.1,2 In general, chemokine receptors interact with
multiple endogenous chemokines, such as CCL2, CCL7, and
CCL8 in the case of CCR2, and CCL3, CCL4, and CCL5 in
the case of CCR5.1 Furthermore, most chemokines can
interact with multiple chemokine receptors, allowing for a
very complex and fine-tuned system.3,4 Dysregulation of this
system has been linked to the development of several
pathophysiological conditions. For example, both CCR2 and
CCR5 have been implicated in many inflammatory and
immune diseases such as rheumatoid arthritis, multiple
sclerosis, atherosclerosis, diabetes mellitus, and psoriasis,5,6
rendering these proteins attractive targets for the pharmaceut-
ical industry. As a result, many efforts have been made to bring
CCR2 and CCR5 small-molecule antagonists into the clinic
although with limited success. Only maraviroc, an HIV-1 entry
inhibitor selectively targeting CCR5, has been approved by the
FDA and EMA,7 while all other drug candidates have failed in
clinical trials.
Recently, it has been suggested that the development of
multitarget drugs (designed to interact with multiple
receptors) represents a more effective approach in the
treatment of complex multifactorial diseases.8,9 Thus, dual
targeting of CCR2 and CCR5 emerges as a potentially more
efficacious strategy in diseases where both receptors are
involved. Indeed, combined CCR2/CCR5 inhibition has
resulted in beneficial effects in several preclinical disease
models and clinical studies, further supporting the use of dual
antagonists.10−12 In this regard, several antagonists with dual
CCR2/CCR5 activity have been reported in the past years,
including the first dual antagonist TAK-779 and the clinical
candidate cenicriviroc.13 All of these antagonists bind to the
extracellular region of CCR2 and CCR5, in a site overlapping
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with the chemokine’s binding pocket.14 Yet the crystal
structures of CCR2 and CCR9 have demonstrated that
chemokine receptors can also be targeted with intracellular
allosteric modulators.15,16 These intracellular ligands offer a
number of advantages, such as noncompetitive binding and, as
a consequence, insurmountable inhibition, which is particularly
important due to the high local concentration of chemokines
during pathological conditions.17,18 In addition, the high
conservation of this intracellular site allows for the design of
multitarget antagonists.18,19 Several high-affinity intracellular
ligands have been already identified for CCR220,21 but not for
CCR5, although intracellular compounds developed for CCR2
or CCR4 have been reported to bind CCR5 with much lower
potency.21,22
In the current study we first report that previously patented
CCR2 antagonists with a triazolopyrimidinone scaffold, such as
compound 8 (Figure 1),23 bind to the intracellular site of the
receptor with high affinity. In addition, we show that this
compound is able to inhibit CCR5 with moderate activity,
suggesting a potential dual CCR2/CCR5 activity for this class
of compounds. Thus, a series of novel and previously reported
triazolopyrimidinone derivatives were synthesized according to
published methods23 in order to obtain structure−affinity/
activity relationships (SARs) in both CCR2 and CCR5.
Radioligand binding assays and functional assays were used to
evaluate their affinity toward CCR2 and activity toward CCR5.
In addition, characterization of two selected compounds (39
and 43) in a [35S]GTPγS binding assay demonstrated that
these compounds inhibit both receptors in a noncompetitive,
insurmountable manner. Finally, selected compounds were
docked into the CCR2 crystal structure in order to shed light
on the binding mode of these derivatives, in comparison to
that of the crystallized CCR2-RA-[R].15 In summary, our
findings provide some insight on the CCR2/CCR5 selectivity
profile of triazolopyrimidinone derivatives, as well as on the
Figure 1. Chemical structures of the orthosteric CCR2/CCR5 antagonist TAK-779 and the CCR2 intracellular ligands CCR2-RA-[R], SD-24, JNJ-
27141491 and the triazolopyrimidinone derivative 8. [3H]-CCR2-RA-[R] was used in radioligand binding assays for CCR2.
Scheme 1. Synthesis Scheme of the Triazolopyrimidinone Derivatives 6−43a
aReagents and conditions: (i) NaH, n-BuLi, THF, overnight, 0 °C to rt (1a−e,i,l,m were commercially available); (ii) DIPEA, LiCl, THF, reflux,
overnight; (iii) (8−43, R2 = NH2) BMIM-PF6, 200 °C, 1 h or (6, R2 = H) H3PO4, EtOH, 170 °C, 10 h or (7, R2 = Me) p-toluenesulfonic acid
monohydrate, 180 °C, 30 min.
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structural requirements for the design of multitarget or
selective intracellular ligands for these receptors.
■ RESULTS AND DISCUSSION
Chemistry. Triazolo-pyrimidinone derivatives 6−43 were
synthesized using a three-step synthesis approach as described
by Bengtsson et al.23 (Scheme 1). First, if not commercially
available, the β-keto esters 1a−n were synthesized from ethyl
acetoacetate 1a and the respective bromo- or iodoalkanes 2f−
h,j,k or benzyl bromide 2n. Benzylation of the β-keto esters
1a−n with the corresponding R1-substituted benzyl bromides
(3a−v), at reflux, resulted in a series of benzylated β-keto
esters 4aa−na, 4bb−bq, 4eq−ev in yields between 8% and
97% (Scheme 1, Table S1). Finally a cyclization reaction of the
benzylated β-keto esters 4aa−na, 4bb−bq, 4eq−ev with the
commercially available 3,5-diaminotriazole 5c in ionic liquid
BMIM-PF6 (1-butyl-3-methylimidazolium hexafluorophos-
phate) at 200 °C under microwave irradiation resulted in
final compounds 6, 9−43 in yields ranging from 4% to 83%.
Final compound 7 (R2 = H) was synthesized using H3PO4 in
ethanol conditions and 8 (R2 = Me) in p-toluenesulfonic acid
monohydrate conditions.
Biology. We have previously identified several CCR2
intracellular ligands belonging to different chemical scaffolds,
such as CCR2-RA-[R], SD-24, and JNJ-27141491 (Figure
1).20,21 In contrast to CCR2 orthosteric ligands, these
intracellular ligands lack a basic nitrogen and have lower
molecular weights, unsaturated systems with haloarenes, and
acidic groups capable of forming hydrogen bonds.18,20 Other
CCR2 antagonists with similar features have been described in
the literature, including the triazolo- or pyrazolopyrimidinone
derivatives described in two different patents.23,24 To test
whether they also bind to the intracellular site of the receptor,
we synthesized “example 1” from the patent by Bengtsson et
al.,23 corresponding to the triazolopyrimidinone derivative 8 in
our study (Figure 1). Using a [3H]-CCR2-RA-[R] binding
assay as previously described,19 we found that compound 8
fully displaced [3H]-CCR2-RA-[R] binding from U2OS cells
stably expressing hCCR2b (U2OS-CCR2) with high affinity
and a pseudo-Hill slope (nH) close to unity, indicating a
competitive interaction with [3H]-CCR2-RA-[R] for the
intracellular binding site. 8 displaced [3H]-CCR2-RA-[R]
with a pKi of 8.90 ± 0.04 (Ki = 1.3 nM, Figure 2a and
Table 1), consistent with its previously reported activity in a
CCR2 calcium flux assay (IC50 = 16 nM).
23
Previous studies have shown that some of these intracellular
ligands are able to bind and inhibit multiple chemokine
receptors, enabling the design of selective and multitarget
inhibitors.19,21,22 In this regard, CCR5 is the closest homolog
to CCR2, with >90% sequence similarity of their intracellular
binding pockets. From the main interactions of CCR2-RA-[R]
to CCR2, only Val2446×36 is exchanged to Leu2366×36 in
CCR515 (residues named according to structure-based
BallesterosWeinstein nomenclature25). Thus, we investi-
gated whether compound 8 is also able to inhibit the highly
homologous CCR5. However, the much lower affinity of [3H]-
CCR2-RA-[R] for CCR5 compared to CCR2 hindered us
from performing radioligand binding assays.21 Thus, we
assessed the CCR5 activity of 8 with a functional β-arrestin
recruitment assay after stimulation with CCL3, one of the
endogenous agonists of CCR5. For this assay, we also included
the intracellular ligands CCR2-RA-[R], SD-24 and JNJ-
27141491, as well as the CCR2/CCR5 orthosteric antagonist
TAK-779 as a positive control (Figure 1), since it is a potent
CCR5 antagonist in a variety of functional assays.26,27
In this assay, CCL3 induced β-arrestin recruitment to U2OS
cells stably expressing hCCR5 (U2OS-CCR5) with a pEC50 of
8.3 ± 0.08 (6 nM) (Figure S1a), similar to values reported in
the literature.28 As expected, TAK-779 was able to completely
inhibit β-arrestin recruitment induced by an EC80 concen-
tration of CCL3 (pEC80 = 7.9 ± 0.08), when tested at a single
concentration of 1 μM (Figure S1b). In contrast, none of the
intracellular ligands were able to fully inhibit CCL3-induced β-
Figure 2. Characterization of ligands in U2OS-CCR2 and U2OS-
CCR5. (a) [3H]-CCR2-RA-[R] displacement by increasing concen-
trations of triazolopyrimidinone derivatives 8, 39, and 43 in U2OS-
CCR2 at 25 °C. Data are normalized to specific binding in the
absence of compound (set as 100%). (b) Inhibition of CCL2-
stimulated β-arrestin recruitment in U2OS-CCR2 by increasing
concentrations of compounds 8, 39, and 43, after stimulation with an
EC80 concentration of CCL2 (set as 100%). (c) Inhibition of CCL3-
stimulated β-arrestin recruitment in U2OS-CCR5 by increasing
concentrations of compounds 8, 39, and 43, after stimulation with an
EC80 concentration of CCL3 (set as 100%). All data are from single,
representative experiments performed in duplicate.
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arrestin recruitment to the same level as TAK-779; in fact, only
compound 8 displayed more than 70% inhibition when tested
at 1 μM (Figure S1b), while CCR2-RA-[R], SD-24, and JNJ-
27141491 led to approximately 50% inhibition or less at the
same concentration of 1 μM (Figure S1b). Consistent with this
low inhibition in CCR5, it was previously shown that CCR2-
RA-[R], JNJ-27141491, and SD-24 inhibited inositol phos-
phate (IP) formation in CCR5 with 7- to 22-fold lower
potency compared to CCR2 inhibition.21 Preincubation of
U2OS-CCR5 cells with increasing concentrations of TAK-779,
before exposure to CCL3, resulted in an inhibitory potency
(IC50) of 6 nM, consistent with previously reported values
(Table S2).27 Also in agreement with a previous study,21 the
reference intracellular ligand CCR2-RA-[R] inhibited CCL3-
induced β-arrestin recruitment with an IC50 value of 703 nM
(Table S2). Moreover, while TAK-779 inhibited CCL3-
induced β-arrestin recruitment with a pseudo-Hill slope close
to unity (nH = −1.1), CCR2-RA-[R] inhibition showed a
significantly higher Hill slope (nH = −2.4), indicative of two
different binding sites for CCL3 and CCR2-RA-[R] (Table
S2).29
As compound 8 was the best CCR5 inhibitor in this assay,
displaying an IC50 value of 571 nM and a Hill slope of −2.2 ±
0.3 (Figure 2c and Table 1), we then synthesized several
triazolopyrimidinone derivatives to explore their structure−
affinity/activity relationships (SARs) in CCR2 and CCR5. All
synthesized triazolopyrimidinone derivatives were evaluated in
[3H]-CCR2-RA-[R] binding assays to determine their binding
affinity for CCR2 and in β-arrestin recruitment assays to
determine their activity toward CCR5 (Figure 2 and Tables
1−3). In CCR5, compounds were first screened at a
concentration of 1 μM, as we were only interested in dual-
targeting compounds with moderate to high potencies (IC50 <
1 μM). For the same reason, only those that displayed >70%
inhibition at this concentration were further evaluated in a
concentration−inhibition curve to determine their potency.
For better comparison, compounds 8, 39, and 43 were also
tested in a CCR2 β-arrestin recruitment assay as previously
described (Figure 2b).20 Finally, we determined the mecha-
nism of inhibition of 39 and 43 in both CCR2 and CCR5
using a [35S]GTPγS binding assay (Figure 3, Table 4).
Structure−Affinity/Activity Relationships (SARs) in
CCR2 and CCR5. Analysis of the triazolopyrimidinone
derivatives started by modifying the amino group (R2) of the
triazolo moiety (R2, Table 1). Compared to 8, removing the
amino group (6) resulted in a similar affinity toward CCR2, in
agreement with the similar reported IC50 values of approx-
imately 20 nM for both compounds, when tested in a calcium
flux assay.23 However, in CCR5 6 displayed a lower potency, as
the inhibition of CCL3-stimulated recruitment of β-arrestin
decreased to 60%, compared to 76% inhibition by 8. The
introduction of a methyl group in R2 (7) was less favorable for
both receptors, as both affinity for CCR2 and activity to CCR5
were reduced compared to 8. As compound 8 displayed the
highest affinity/activity for both receptors, we decided to keep
the amino group in R2 and explore different phenyl
substituents (R1, Table 1), taking 8 as the starting point.
Compared to 8, the unsubstituted 9 showed a 5-fold
decrease in affinity toward CCR2, while in CCR5 it was only
able to inhibit 35% of the receptor response at 1 μM. Next, we
investigated the effect of several benzyl modifications,
including the influence of different substituent positions
(Table 1). In the case of CCR2, meta-substituted derivatives
yielded the highest affinities in this series of compounds (13−
18), whereas ortho-substituted derivatives yielded the lowest
(10−12). None of the ortho-substitutions led to an improve-
ment in affinity over 8 or the unsubstituted 9. Introduction of a
methyl (10) or a chloro (11) group in this position resulted in
affinities lower than 10 nM, while the introduction of an
electron-donating methoxy group further reduced the affinity
to 105 nM (12), displaying the lowest CCR2 affinity in this
series (Table 1). Moving the methyl group to meta (13) or
para (19) position slightly improved the CCR2 binding affinity
compared to 9, achieving the highest affinity in meta position
(19, 3 nM). Similarly, moving the methoxy group to meta or
para position resulted in improved affinities following the meta
> para > ortho order; however, the affinities remained lower
than 10 nM (17, 13 nM; 23, 21 nM), with no improvement
over 9. This is consistent with functional data reported in the
patent by Bengtsson et al., where similar compounds with a
methoxybenzyl moiety displayed a loss of CCR2 activity
compared to the unsubstituted-phenyl analogue.23 Substitution
of the meta methoxy group by an electron-withdrawing CF3
Table 1. Characterization of Compounds 6−23 in hCCR2
and hCCR5a
hCCR2 hCCR5




inhibition at 1 μM
(%)c
6 3-Cl H 8.76 ± 0.01 (1.7) 60%
7 3-Cl Me 8.46 ± 0.05 (3.5) 35%
8 3-Cl NH2 8.90 ± 0.04 (1.3) 6.24 ± 0.004 (571)
9 H NH2 8.27 ± 0.10 (5.9) 35%
10 2-Me NH2 7.81 ± 0.05 (15.7) 28%
11 2-Cl NH2 7.84 ± 0.03 (14.5) 27%
12 2-OMe NH2 6.98 ± 0.04 (104.6) −20%d
13 3-Me NH2 8.61 ± 0.03 (2.5) 62%
14 3-F NH2 8.53 ± 0.18 (3.4) 43%
15 3-Br NH2 9.08 ± 0.06 (0.9) 60%
16 3-I NH2 9.06 ± 0.02 (0.9) 66%
17 3-OMe NH2 7.89 ± 0.07 (13.0) −27%d
18 3-CF3 NH2 8.26 ± 0.09 (5.9) 36%
19 4-Me NH2 8.46 ± 0.03 (3.5) −57%d
20 4-F NH2 8.39 ± 0.03 (4.1) 31%
21 4-Cl NH2 8.74 ± 0.05 (1.8) 31%
22 4-Br NH2 8.84 ± 0.02 (1.5) 14%
23 4-OMe NH2 7.68 ± 0.05 (20.9) −28%
aData are presented as the mean pKi/pIC50 ± standard error of the
mean (SEM) and mean Ki/IC50 (nM) of at least three independent
experiments performed in duplicate. bpKi values from the displace-
ment of ∼6 nM [3H]-CCR2-RA-[R] from U2OS cells stably
expressing CCR2, at 25 °C. cPercent inhibition of β-arrestin
recruitment in U2OS cells stably expressing CCR5 by 1 μM
compound, in the presence of CCL3 (pEC80 = 7.9). pIC50 values
were determined for compounds displaying more than 70% inhibition.
% Inhibition values are presented as means values of at least two
independent experiments, performed in duplicate. dNo inhibition was
observed at the concentration of 1 μM; instead some CCL3
stimulation was measured.
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group resulted in improved affinity over 17 (18, 6 nM) but no
improvement over the unsubstituted 9.
The effect of introducing different halogen groups was first
investigated in the meta position. Overall, an increase in size
and lipophilicity from fluoro to iodo resulted in improved
binding affinities toward CCR2 (F, 14 < Cl, 8 < Br, 15 ≈ I,
16). In fact, compounds 15 and 16 displayed the highest
affinities in this series of derivatives (15, 0.8 nM; 16, 0.9 nM).
Moving the halogen substituents to the para position resulted
in a similar trend in affinity (F, 20 < Cl, 21 < Br, 22); however,
their affinities were lower compared to the meta-substituted
analogues. Of note, compounds with a fluorine atom in meta
(14) or para (20) position displayed lower affinities than
compounds with a methyl group in the equivalent position (13
and 19). To gain more insight in a potential relationship
between affinity and lipophilicity as observed in the halogen
series, calculated log P values (cLogP) of compounds 8−23,
with R1 modifications, were plotted against their pKi values in
CCR2. This analysis revealed only a slight correlation between
these two parameters for this set of compounds (Figure S2a);
however, this correlation was lost when all synthesized
derivatives were included in this plot (Figure S2b), indicating
that this is not a general trend.
In the case of CCR5, meta-substituted derivatives also
outperformed their ortho- and para-substituted analogues, with
some compounds displaying >60% inhibition at 1 μM; in
contrast, ortho- and para-substitution resulted in compounds
with low (≤31%) to marginal efficacy in CCR5, suggesting that
substituents in ortho or para position are not tolerated in
CCR5. Similarly as in CCR2, the introduction of a methoxy
group was unfavorable, as it led to a complete loss of activity in
CCR5 when tested at 1 μM (12, 17, and 23), regardless of the
position, whereas electron-withdrawing groups in meta
position (18, R2 = CF3) did not bring any improvement
over the unsubstituted 9. Except for compound 14 bearing a
meta-fluoro, which showed less than 45% inhibition, all other
compounds bearing halogens in meta position led to >60%
inhibition; the same was achieved when a methyl group was
placed in this position (13). Overall, these data indicate that
meta-substituents, especially halogens, are preferred to achieve
dual CCR2/CCR5 activity, while ortho- and para-substituents
lead to a lower affinity but higher selectivity toward CCR2.
As none of the other substituents in R2 led to a significant
improvement in CCR5 activity over compound 8, we decided
to continue with this compound and investigate the effect of
replacing the cyclopropyl moiety in R3. On the basis of the
chemical structure of 8 and CCR2-RA-[R] (Figure 1), we
hypothesized that the cyclopropyl group in 8 interacts with
Val2446×36 in CCR2 in a similar manner as the cyclohexyl
group of CCR2-RA-[R].15 Thus, several triazolopyrimidinone
derivatives were synthesized with different alkyl chains and
aromatic groups in this position in order to investigate their
SARs (Table 2). Starting with the effect of alkyl substituents,
we observed that increasing the size and flexibility of the alkyl
chain from n = 1 (methyl) to n = 4 (butyl) resulted in a parallel
increase in CCR2 affinity (17 nM for R3 = Me (24); ∼4 nM
for R3 = Et (25) and R3 = Pr (26); 2 nM for R3 = Bu (28)).
However, further elongation of the chain length (n = 5−7) led
to a progressive drop in affinity (7 nM for R3 = Pent (30); 22
nM for R3 = Hex (32); 178 nM for R3 = Hept (28)),
indicating that linear alkyl chains longer than five carbons
might not fit in this hydrophobic pocket. The same trend was
Figure 3. Characterization of compounds 39 and 43 as insurmountable, negative allosteric modulators using a [35S]GTPγS binding assay in
hCCR2 and hCCR5. Effect of increasing concentrations of 39 and 43 in a CCL2-stimulated [35S]GTPγS binding in U2OS-CCR2 (a, b) or in a
CCL3-stimulated [35S]GTPγS binding in U2OS-CCR5 (c, d), at 25 °C. Parameters obtained from the concentration−response curves (pEC50,
Emax) are summarized in Table 4. Data are presented as mean ± SEM values of three experiments performed in duplicate.
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observed for CCR5 activity, as only the n-propyl (26) and n-
butyl (28) substituted compound led to >60% inhibition,
albeit without improvement over 8 (28, 519 nM). Moreover,
introduction of a hexyl or heptyl group resulted in CCL3
stimulation instead of inhibition, which was not further
investigated. Increasing bulkiness via branching of alkyl groups
or substitution with aliphatic rings enhanced the affinity
toward CCR2, indicating that these substituents might provide
a better interaction with the receptor. For instance, the
introduction of both isopropyl (27) and cyclopropyl (8)
groups led to an improvement in CCR2 affinity compared to
the linear analogue 26. Moreover, compound 27 with an
isopropyl substituent also yielded a 2-fold increase in CCR5
potency compared to the cyclic analogue 8, displaying the
highest potency in this series of compounds (27, 281 nM). In
line with this trend, we observed that replacing the linear
pentyl group (30) with a cyclopentyl group (31) was also
beneficial for CCR2, as this derivative showed a 4.5-fold
increased affinity compared to 30 (31, 1.6 nM). In CCR5, 31
inhibited the CCL3-induced response with a potency of 388
nM, showing a slight improvement over compound 8. In
contrast, the introduction of a 2-ethylbutyl group (29) resulted
in reduced affinity/activity toward both CCR2 and CCR5.
These data suggest that the isopropyl group is the preferred R3
substituent when designing CCR2/CCR5 dual antagonists, as
this substituent led to the highest potency in CCR5 while
maintaining a high affinity for CCR2. Next, inspired by our
work on CCR1/CCR2 selectivity of pyrrolone derivatives,19
we investigated whether aromatic substituents are tolerated in
this position. As expected from previous studies,19,30 the
introduction of aromatic groups decreased 20-fold (34, 27
nM), 40-fold (36, 52 nM), and 122-fold (35, 159 nM) the
affinity for CCR2 compared to 8. When tested in CCR5, all
derivatives showed a complete loss of activity at 1 μM,
indicating that aromatic groups are not favorable for selectivity
or dual activity.
With the aim of finding dual CCR2/CCR5 intracellular
inhibitors, we kept the isopropyl moiety in R3 and investigated
the effect of having a disubstituted phenyl moiety in R1 by
exploring different positions and combinations of chlorine and
bromine atoms (Table 3). First and similar to 8, we kept the
cyclopropyl moiety in R3 and combined it with dichlorination
in meta and para positions (37). Compared to the
monosubstituted analogues 8 and 21, this compound yielded
an even higher affinity to CCR2 (37, 0.4 nM); moreover, its
ability to inhibit CCL3-induced response in CCR5 was also
improved, as the potency increased to 214 nM. By replacing
the cyclopropyl of 37 with an isopropyl group (38), we
retained affinity for CCR2 (0.6 nM), but the potency for
CCR5 increased by almost 2-fold (132 nM), in agreement with
the higher potency observed in 27 versus 8 (Table 2). Moving
one chlorine atom to the ortho position, while keeping one in
the adjacent meta position, yielded compound 39 with slightly
lower affinity for CCR2 but even higher potency in CCR5 (39,
84 nM), indicating that although ortho substituents are not
preferred in monosubstituted derivatives, they are still
tolerated when placed in combination with halogens in other
positions. However, placing the two halogens in the second
and fifth positions was clearly detrimental for both receptors
(40); in CCR2, the affinity decreased by almost 40-fold, while
Table 2. Characterization of Compounds 24−36 in hCCR2
and hCCR5a
hCCR2 hCCR5
compd R3 pKi ± SEM (Ki, nM)
b
pIC50 ± SEM (IC50, nM)
or inhibition at 1 μM (%)c
8 cPr 8.90 ± 0.04 (1.3) 6.24 ± 0.004 (571)
24 Me 7.78 ± 0.07 (17.2) −35%
25 Et 8.40 ± 0.07 (4.0) 29%
26 Pr 8.46 ± 0.07 (3.6) 64%
27 iPr 8.72 ± 0.05 (1.9) 6.56 ± 0.05 (281)
28 Bu 8.64 ± 0.03 (2.3) 6.29 ± 0.05 (519)
29 2-EtBu 8.20 ± 0.04 (6.4) 29%
30 Pent 8.14 ± 0.03 (7.2) 38%
31 cPent 8.81 ± 0.04 (1.6) 6.43 ± 0.08 (388)
32 Hex 7.66 ± 0.02 (22.0) −63%d
33 Hept 6.76 ± 0.05 (178.1) −265%d
34 Ph 7.64 ± 0.17 (26.7) −41%d
35 4-MePh 6.81 ± 0.07 (158.8) −13%d
36 CH2CH2Ph 7.29 ± 0.05 (52.3) −42%d
aData are presented as the mean pKi/pIC50 ± standard error of the
mean (SEM) and mean Ki/IC50 (nM) of at least three independent
experiments performed in duplicate. bpKi values from the displace-
ment of ∼6 nM [3H]-CCR2-RA-[R] from U2OS cells stably
expressing CCR2, at 25 °C. cPercent inhibition of β-arrestin
recruitment in U2OS cells stably expressing CCR5 by 1 μM
compound, in the presence of CCL3 (pEC80 = 7.9). pIC50 values
were determined for compounds displaying more than 70% inhibition.
% Inhibition values are presented as mean values of at least two
independent experiments, performed in duplicate. dNo inhibition was
observed at the concentration of 1 μM; instead some CCL3
stimulation was measured.









inhibition at 1 μM
(%)c
37 3,4-diCl cPr 9.35 ± 0.05 (0.4) 6.67 ± 0.03 (214)
38 3,4-diCl iPr 9.22 ± 0.05 (0.6) 6.91 ± 0.09 (132)
39 2,3-diCl iPr 8.81 ± 0.07 (1.6) 7.09 ± 0.07 (84)
40 2,5-diCl iPr 7.65 ± 0.03 (22.5) 20%
41 3,5-diCl iPr 8.66 ± 0.05 (2.2) 6.49 ± 0.06 (336)
42 3,5-diBr iPr 8.68 ± 0.01 (2.1) 64%
43 3-Br, 4-Cl iPr 9.42 ± 0.02 (0.4) 6.95 ± 0.04 (115)
aData are presented as mean pKi/pIC50 ± standard error of the mean
(SEM) and mean Ki/IC50 (nM) of at least three independent
experiments performed in duplicate. bpKi values from the displace-
ment of ∼6 nM [3H]-CCR2-RA-[R] from U2OS cells stably
expressing CCR2, at 25 °C. cPercent inhibition of β-arrestin
recruitment in U2OS cells stably expressing CCR5 by 1 μM
compound, in the presence of CCL3 (pEC80 = 7.9). pIC50 values
were determined for compounds displaying more than 70% inhibition.
% Inhibition values are presented as mean values of at least two
independent experiments, performed in duplicate.
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in CCR2, the compound was only able to inhibit 20% of the
CCR5 response. Placing the two halogens in the symmetrical
third and fifth positions restored the affinity/activity in both
receptors (41, 2.2 nM in CCR2 and 336 nM in CCR5).
Replacing the two chlorine atoms of 41 by bromine atoms
yielded derivative 42, which retained affinity toward CCR2 but
led to decrease in CCR5 activity, as this compound was not
able to inhibit >70% of the CCL3-induced response. Finally,
the combination of a bromo in meta position with a chloro in
para position (42) improved both the affinity and activity to
both receptors to similar levels as 37, in the case of CCR2, and
38 in the case of CCR5, indicating that halogens in adjacent
positions are more favorable for activity in these receptors. Of
note, compounds 37, 38, and 43 displayed the highest affinities
to CCR2 in this study, while 38, 39, and 43 displayed the
highest potencies to CCR5.
It is important to note that so far we are comparing data not
only between two different receptors but also between two
different assays: (i) a radioligand binding assay for CCR2, in
the absence of agonist, which allows the determination of true
affinities (pKi values); (ii) a functional assay for CCR5 in the
presence of an EC80 concentration of CCL3, without further
correction of their IC50 values. To better compare the activities
in both receptors, we selected starting compound 8 as well as
compounds 39 and 43 (with the highest potency on CCR5
and the highest affinity for CCR2, respectively) and tested
these in a previously described β-arrestin recruitment assay for
CCR2.20 In this assay, compound 8 inhibited CCL2-stimulated
β-arrestin recruitment with a potency of 10 nM and a Hill
slope of −2.7, in agreement with its allosteric binding mode.
Compound 39 inhibited β-arrestin recruitment in CCR2 with a
lower potency of 21 nM, while compound 43 displayed a
higher potency of 4 nM, consistent with their affinities. In
addition, their Hill slopes (nH = −2.5 for 39; nH = −3.4 for 43)
are also indicative of a noncompetitive form of inhibition, a
further confirmation of their allosteric binding site located in
the intracellular region of CCR2 (Figure 2b and Table S3). Of
note, the Hill slopes in CCR5 were comparable to those in
CCR2 (nH = −3.7 for 39; nH = −4.4 for 43), i.e., indicating an
allosteric interaction at CCR5 as well. Comparing the IC50
values obtained with the functional assays in both receptors, we
observe a 4-fold difference between CCR2 and CCR5 in the
case of 39, making it a potential dual-antagonist for both
receptors. In contrast, the potencies in CCR2 and CCR5 differ
by 29-fold in the case of 43, indicating a higher selectivity
toward CCR2. Yet, network studies have suggested that partial
inhibition by a low-affinity binder might be sufficient to
effectively modulate cellular pathways in vivo;31 thus further
studies are needed to establish the optimal activity ratio for
these receptors in order to achieve in vivo efficacy.32
Mechanism of Inhibition of Selected Compounds.
Selected compounds 39 and 43 were also tested in a
[35S]GTPγS binding assay in both CCR2 and CCR5 in
order to determine their mechanism of inhibition. In the case
of CCR2, we have shown that these ligands fully displace [3H]-
CCR2-RA-[R], indicating that triazolopyrimidinone derivatives
bind in the same intracellular binding site. Thus, these
compounds were expected to show noncompetitive, insur-
mountable antagonism to (orthosteric) chemokine ligands, as
previously demonstrated in CCR2 with CCR2-RA-[R]20 and
JNJ-27141491.33 To verify this, 39 and 43 were characterized
in a previously described [35S]GTPγS binding assay on U2OS-
CCR2 membranes.20 In this assay, CCL2-stimulation of
[35S]GTPγS binding in CCR2 was examined in the absence
or presence of fixed concentrations of 39 and 43 (Table 4 and
Figure 3a,b). In the absence of antagonist, increasing
concentrations of CCL2 induced [35S]GTPγS binding with
an EC50 of 8 nM, in line with previously described
parameters.19,20 Co-incubation of CCL2 with 39 or 43 caused
a significant reduction in the maximal response of CCL2
(Emax) at all three antagonist concentrations tested. The lowest
concentrations of antagonist did not affect the potency of
CCL2, while higher concentrations significantly reduced the
potency of CCL2 (Table 4 and Figure 3a,b). Of note, both
compounds were also tested in the absence of CCL2 at a single
concentration of 1 μM to determine potential inverse agonism.
At this concentration they only reduced the basal [35S]GTPγS
binding levels by 7−8% (Figure S3), providing too small a
window to accurately determine their potencies as inverse
agonists. Previously, we reported that some intracellular
pyrrolone derivatives were also able to decrease the CCR2
basal activity in this assay; however, the effect seemed to be
dependent on the assay conditions, such as GDP concen-
trations.19 Thus, more studies are needed to investigate
whether the observed CCR2 constitutive activity is biologically
relevant.
To confirm our hypothesis that these two compounds also
bind to an allosteric site in CCR5, i.e., the intracellular binding
site, we next analyzed the effect of 39 and 43 on CCL3-
induced [35S]GTPγS binding in U2OS-CCR5 membranes. In
agreement with previous studies, CCL3 stimulated
[35S]GTPγS binding in CCR5 with a potency of 4 nM.28
Similarly as in CCR2, the two compounds were able to
significantly suppress the maximal response induced by CCL3
Table 4. Effects of Compounds 39 and 43 in Chemokine-
Stimulated [35S]GTPγS Bindinga
receptor compd




hCCR2 CCL2 8.10 ± 0.06 (8) 107 ± 2
CCL2 + 10 nM 39 7.89 ± 0.04 (13) 91 ± 1**
CCL2 + 30 nM 39 7.60 ± 0.07 (26)** 75 ± 4****
CCL2 + 100 nM
39
7.27 ± 0.10 (56)**** 50 ± 3****
CCL2 + 1 nM 43 7.91 ± 0.10 (13) 72 ± 4****
CCL2 + 3 nM 43 7.53 ± 0.12 (32)*** 51 ± 5****
CCL2 + 10 nM 43 6.87 ± 0.13 (148)**** 33 ± 3****
hCCR5 CCL3 8.42 ± 0.06 (4) 108 ± 2
CCL3 + 100 nM
39
8.35 ± 0.09 (5) 79 ± 5****
CCL3 + 300 nM
39
8.14 ± 0.12 (8) 56 ± 2****
CCL3 + 1000 nM
39
8.14 ± 0.17 (9) 25 ± 4****
CCL3 + 30 nM 43 8.30 ± 0.05 (5) 81 ± 3****
CCL3 + 100 nM
43
8.21 ± 0.05 (6) 58 ± 1****
CCL3 + 300 nM
43
8.05 ± 0.06 (9)* 35 ± 2****
aData represent the mean ± standard error of the mean (SEM) of
three independent experiments performed in duplicate. One-way
ANOVA with Dunnett’s post hoc test was used to analyze differences
in pEC50 and Emax values against CCL2 or CCL3 controls.
bMaximum
effect (Emax) of CCL2 or CCL3 measured in the absence or presence
of fixed concentrations of compound 39 and 43 in CCR2 or CCR5,
respectively.
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at all concentrations tested (Table 4 and Figure 3c,d).
However, in contrast to CCR2, the potency of CCL3 was
only significantly reduced with the highest concentration of 43
(Table 4). Such depression of the maximal response with or
without a decrease of agonist potency is typical of
insurmountable antagonists,34 indicating that 39 and 43
behave as insurmountable antagonists at both CCR2 and
CCR5. Of note, insurmountable antagonism can be generally
achieved by two different mechanisms: allosteric binding or
slow binding kinetics, i.e., slow equilibration of a competitive
antagonist.34 However, insurmountable inhibition due to
hemiequilibrium is only evident in preincubation experiments,
where the receptor is preincubated with the antagonist before
exposure to the agonist.34 In contrast, allosteric binding leads
to insurmountable inhibition in co-incubation experiments, as
performed in this study. These data further support our
hypothesis that 39 and 43 bind to an allosteric binding site in
CCR5, most probably located intracellularly.
Docking Study. To further investigate the binding mode
of triazolopyrimidinone derivatives, compounds 8, 39, 40, and
43 were docked into a CCR2b model based on the crystal
structure of CCR2 (PDB code 5T1A, Figures 4 and S4).15 Due
to the close proximity to the intracellular binding site, several
residues from the intracellular loop 3 (ICL3) had to be
modeled based on the crystal structure of CCR5 (PDB code
4MBS),35 since they were mutated in the original CCR2
crystal structure to further stabilize the receptor. As seen in
Figure 4a, 43 was predicted to adopt a similar binding pose as
that of the previously cocrystallized ligand CCR2-RA-[R].15
The disubstituted phenyl group of 43 was constrained to
overlap with the corresponding phenyl group of CCR2-RA-
[R], since the disubstituted aromatic rings of JNJ-27141491
and SD-24 (Figure 1) were also predicted to overlay with the
phenyl group of CCR2-RA-[R] in a previous study.21
However, the bromine group of compound 43 is predicted
to form a halogen bond with the backbone of Val1×53, which
might contribute to the higher affinity of 43 versus CCR2-RA-
[R] (Figure 4b). The positions of the halogens in this phenyl
group might also explain the results of our SAR study. For
instance, compound 40 with no halogen group on position 3 is
not able to form halogen bonds with the receptor; in addition,
one of the chlorine groups seems to point upward toward
Tyr7×53, resulting in a sterically unfavorable position and thus
in the observed lower activity (Figure S4 and Table 3). Similar
to 43, both 8 and 39 contain a chlorine group in position 3,
promoting the formation of a halogen bond with the backbone
of Val1×53, which might result in the improved activity
compared to 40 (Figure S4 and Table 3). However, bromine
displays a larger σ-hole and therefore a higher halogen bond
strength compared to chlorine,36 which might result in the
higher affinity of 43, containing a bromine group, compared to
8 or 39 containing a chlorine. As the SAR follows a similar
trend in CCR5, these data suggest that the intracellular ligands
share similar interactions between the aromatic group and both
receptors (Table 3).
In addition, the isopropyl group present in compounds 39,
40, and 43 is predicted to bind in the same position as the
cyclohexyl moiety of CCR2-RA-[R], although it seems to make
less interactions with Val6×36 perhaps due to the slightly
different ligand orientation (Figure 4b). Previous studies have
confirmed the crucial role of Val6×36 for binding affinity of
some intracellular ligands in CCR2, as mutation of this residue
to alanine completely abolished binding of CCR2-RA-[R] to
the receptor.21 Moreover, this residue might be involved in
target selectivity, as the main difference between the
intracellular pockets of CCR2 and CCR5 is the single
substitution of Val6×36 by Leu6×36. The steric hindrance
introduced by this substitution might thus be responsible for
the reduction in activity of CCR2-RA-[R] and the triazolo-
pyrimidinone derivatives toward CCR5 compared to CCR2.21
Indeed, in the case of CCR5, only small aliphatic groups were
tolerated in R3 position, such as cyclopropyl or isopropyl
(Table 2), while bigger aliphatic groups resulted in improved
selectivity toward CCR2. In line with the role of Val6×36 as
determinant of selectivity, a previous SAR analysis of pyrrolone
derivatives in CCR1, which also contains a leucine in position
6 × 36, showed that aromatic groups in the equivalent R3
position provide CCR1 selectivity versus CCR2, as aromatic
groups are not tolerated in this position in CCR219 (Table 2).
The binding pose of 43 seems to be stabilized by a network
of hydrogen bonds between the triazolopyrimidinone core and
residues E8×48, Lys8×49, F8×50, and R3×50 (Figure 4b). Although
the core of CCR2-RA-[R] and 43 binds with a different
Figure 4. Proposed binding mode of 43 in hCCR2b. (a) Overlay of
43 with the CCR2 intracellular ligand CCR2-RA-[R], showing that 43
interacts in a similar manner as CCR2-RA-[R]. (b) Docking of 43,
displaying the interactions with CCR2. The amino group in R2 makes
an extra hydrogen-bond interaction with E8×48, while the bromine
group in R1 makes an extra halogen bond with the backbone of V1×53,
which might contribute to the improved affinity of 43 to this receptor.
Model of hCCR2 is based on the crystal structure of CCR2 (PDB
code 5T1A),15 and amino acid residues are labeled according to their
structure-based Ballesteros−Weinstein numbers.25
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orientation, the carboxy group of both is overlaid in the same
position, interacting with the backbones of Lys8×49 and F8×50.
Moreover, the secondary and tertiary amino groups present in
the triazolopyrimidinone core also form hydrogen bonds with
the backbones of Lys8×49 and Glu8×48, as well as with the side
chains of Arg3×50. Finally, the primary amino group in position
R2 of compound 43 also makes an extra hydrogen bond with
the side chain of E8×48. Such extended network of hydrogen
bond interactions is not present with CCR2-RA-[R], and thus
it might also be responsible for the higher affinity of 43 in
CCR2, compared to CCR2-RA-[R]. In addition, the SAR data
suggest that this interaction is also crucial in CCR5, as the
removal of this amino group (compounds 6 and 7) was
detrimental for CCR5 activity (Table 1). Previous studies have
confirmed the importance of residues 8 × 49 and/or 8 × 50 in
chemokine receptors for the binding of several intracellular
ligands. For example, alanine mutations of Lys8×49 and F8×50 in
CCR2 caused a 10-fold reduction or a complete loss of affinity
of intracellular ligands, respectively, compared to the wild-type
receptor.21 In CXCR2, alanine mutation of Lys8×49 led to a
reduced affinity of three different intracellular ligands, while
the mutation F8×50A only affected one of the ligands tested,
indicating a different binding mode.37 Moreover, Lys8×49 has
been suggested as a key residue for target selectivity between
CXCR1 and CXCR2, as it is exchanged by Asn8×49 in
CXCR1.38 In addition, the crystal structure of CCR9 in
complex with vercirnon16 also shows a binding interaction
between the ligand and Arg3238×49 and Phe3248×50.
Overall, these data suggest that although the intracellular
pockets of CCR2 and CCR5 are quite conserved, the design of
multitarget compounds is not quite straightforward. Moreover,
several of these residues have been shown to be involved in
Gαi coupling in recent cryoelectron microscopy (cryo-EM)-
derived GPCR structures, including residues 3 × 50, 6 × 29, 6
× 32 to 6 × 37, 8 × 47, and 8 × 49.39−41 Similarly,
homologous residues are also involved in direct interactions
between rhodopsin and arrestin,42 suggesting a direct
interference of these intracellular ligands with the Gαi protein
and β-arrestin binding site, and the possibility of fine-tuning
residue interactions for the design of biased ligands. On the
basis of the SAR analysis and the docking study, these
compounds could be further optimized by exploring the
triazolopyrimidinone core. For instance, pyrazolo-
pyrimidinones have also been described for CCR2,24 which
might also display CCR5 activity. In addition, exploring other
halogen combinations at the phenyl group in R1 or other small,
bulky aliphatic groups in R3 such as cyclobutyl might lead to
compounds with improved dual activity. Although out of the
scope of this manuscript, ligands such as 39 with high potency
in CCR5 could be investigated as potential tools to further
study binding interactions in CCR5, i.e., by obtaining a
radiolabeled tool compound or by obtaining a CCR5 crystal
structure in complex with an intracellular ligand. Finally, these
ligands can be used in future experiments designed to
investigate their functional effects both in vitro and in vivo, to
validate the target combination, and to establish the required
level of target modulation.43
■ CONCLUSIONS
In this study we first confirmed that the triazolopyrimidinone
derivative 8 binds to the intracellular pocket of CCR2 in a
similar manner as the reference intracellular ligand CCR2-RA-
[R]. Moreover, compound 8 was also able to inhibit CCR5 in a
functional β-arrestin recruitment assay; thus, we took this
compound as a starting point for the synthesis of a series of
novel and previously described triazolopyrimidinone deriva-
tives. Using [3H]-CCR2-RA-[R] binding assays and functional
β-arrestin recruitment assays, we explored structure−affinity/
activity relationships (SARs) in both receptors. Overall, these
compounds were mostly selective toward CCR2; however,
CCR5 activity was increased with the combination of a
primary amino group in R2 position, an isopropyl moiety in R3,
and two halogens placed in adjacent positions at the phenyl
group in R1. Overall, these findings indicate that even though
the intracellular pockets of CCR2 and CCR5 are highly
conserved, selectivity of intracellular ligands can be fine-tuned,
allowing the design of either selective or multitarget ligands.
Evaluation of compounds 39 and 43 in a [35S]GTPγS binding
assay indicates that both compounds display a noncompetitive,
insurmountable mode of inhibition in CCR2 and CCR5, which
might represent a therapeutic advantage in inflammatory
diseases characterized by a high local concentration of
endogenous chemokines, such as multiple sclerosis and
rheumatoid arthritis. Thus, in diseases where selective
chemokine receptor antagonists have been largely unsuccessful,
the development of multitarget, intracellular ligands for CCR2
and CCR5 is warranted to further study the effects of
multitarget versus selective inhibition, as these ligands may
represent a novel therapeutic option in these diseases.
■ EXPERIMENTAL SECTION
Chemistry. General Methods. All solvents and reagents used
were of analytical grade and from commercial sources. Demineralized
water was used in all cases, unless stated otherwise, and is simply
referred to as H2O. Microwave-based synthesis was carried out using a
Biotage Initiator equipment (Biotage, Sweden). All reactions were
monitored by thin-layer chromatography (TLC) using aluminum
plates coated with silica gel 60 F254 (Merck), and compounds were
visualized under ultraviolet light at 254 nm or via KMnO4 staining.
Column chromatography for compound purification was performed
using silica gel (Merck Millipore) with particle size 0.04−0.63 mm.
Chemical identity of final compounds was established using 1H NMR
and liquid chromatography−mass spectrometry (LC−MS). 1H NMR
spectra were recorded on a Bruker AV 400 liquid spectrometer (1H
NMR, 400 MHz) at room temperature. Compound 39, as one of the
most soluble and one of the best CCR2/CCR5 antagonists, was fully
characterized (1H NMR, 13C NMR, and attached proton test (APT))
on a Bruker AV500 spectrometer at 80 °C. The corresponding NMR
spectra of compound 39 are shown in Figures S5−S7. Chemical shifts
(δ) are reported in parts per million (ppm), and coupling constants
(J) in Hz. Liquid chromatography−mass spectrometry (LC−MS) of
final compounds was performed using a Thermo Finnigan Surveyor
LCQ Advantage Max LC−MS system and a Gemini C18
Phenomenex column (50 mm × 4.6 mm, 3 μm). Analytical purity
of the compounds was determined using a Shimadzu high pressure
liquid chromatography (HPLC) equipment with a Phenomenex
Gemini column (3 x C18 110A column, 50 mm × 4.6 mm, 3 μm). A
flow rate of 1.3 mL/min and an elution gradient of 10−90% MeCN/
H2O (0.1% TFA) were used. The absorbance of the UV
spectrophotometer was set at 254 nm. All compounds tested in
biological assays showed a single peak at the designated retention time
and were ≥95% pure. Sample preparations for HPLC and LC−MS
were as follows unless stated otherwise: 0.3 mg/mL of compound was
dissolved in a 1:1:1 mixture of H2O:MeOH:
tBuOH. Of note, some
compounds required DMSO and heat to ensure proper dissolution.
None of the final compounds were identified as potential pan-assay
interference compounds (PAINS) after assessment with the free
ADME-Tox filtering tool (FAF-Drugs4),44,45 which uses three
different PAINS filters based on Baell et al.46
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General Procedure 1: Synthesis of β-Keto Esters 1f−
h,j,k,n.47 In a flame-dried round-bottom flask under a nitrogen
atmosphere, ethyl acetoacetate (2.53 mL, 20.0 mmol, 1.00 equiv) was
added dropwise to a suspension of NaH (880 mg, 22.1 mmol 1.10
equiv) in dry THF (5 mL) at 0 °C while stirring. After 20 min, n-
butyllithium (20 0.0 mmol, 2.50 M solution in pentane,1.00 equiv)
was added dropwise to the mixture and stirred for further 30 min. The
respective alkyl halide 2f−h,j,k or benzyl bromide 2n (1.20 equiv)
was subsequently added dropwise over a period of 10 min to the
dianion solution after which the solution was allowed to reach rt. After
14 h, the reaction was quenched by the addition of saturated NH4Cl
(aq, 80 mL). The mixture was subsequently extracted with diethyl
ether (2 × 120 mL). The combined organic fractions were washed
with brine (80 mL) and dried over MgSO4 followed by concentration
in vacuo. The crude products were purified by flash chromatography
(CH2Cl2/petroleum ether and/or EtOAc/petroleum ether as the
eluent) to give the title compounds 1f−h,j,k,n as oils. Compounds
1a−e,i,l,m were commercially available.
Ethyl-3-oxoheptanoate (1f).47 Compound 1f was synthesized
according to general procedure 1, using 1-bromopropane (2f, 2.00
mL, 22.0 mmol, 1.10 equiv) as starting compound. Compound was
purified by silica column chromatography (1−30% EtOAc in
petroleum ether). Yield: 36% (1.25 g) as a colorless oil. 1H NMR
(400 MHz, CDCl3) δ 4.19 (q, J = 7.2 Hz, 2H), 3.44 (s, 2H), 2.54 (t, J
= 7.4 Hz, 2H), 1.65−1.55 (m, 2H), 1.38−1.25 (m, 7H), 0.88 (t, J =
6.8 Hz, 3H) ppm.
Ethyl 5-Ethyl-3-oxoheptanoate (1g). Compound 1g was
synthesized according to general procedure 1, using 3-bromopentane
(2g, 3.00 mL, 24.2 mmol, 1.21 equiv) as starting compound.
Compound was purified by silica column chromatography (1−30%
EtOAc in petroleum ether). Yield: 18% (630 mg) as a yellow oil. 1H
NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.2 Hz, 2H), 3.40 (s, 2H),
2.43 (d, J = 6.8 Hz, 2H), 1.88−1.73 (m, 1H), 1.33−1.21 (m, 7H),
0.82 (t, J = 7.4 Hz, 6H) ppm.
Ethyl 3-Oxooctanoate (1h).47 Compound 1h was synthesized
according to general procedure 1, using 1-bromobutane (2h, 2.59 mL,
24.1 mmol, 1.21 equiv) as starting compound. Compound was
purified by silica column chromatography (1−30% EtOAc in
petroleum ether). Yield: 38% (1.41 g) as a yellow oil. 1H NMR
(400 MHz, CDCl3) δ 4.19 (q, J = 7.2 Hz, 2H), 3.43 (s, 2H), 2.53 (t, J
= 7.2 Hz, 2H), 1.65−1.55 (m, 2H), 1.37−1.12 (m, 7H), 0.89 (t, J =
7.2 Hz, 3H) ppm.
Ethyl 3-Oxononanoate (1j).47 Compound 1j was synthesized
according to general procedure 1, using 1-iodopentane (2j, 3.13 mL,
24.0 mmol, 1.20 equiv) as starting compound. Compound was
purified by silica column chromatography (1−30% EtOAc in
petroleum ether). Yield: 44% (1.76 g) as a yellow oil. 1H NMR
(400 MHz, CDCl3) δ 4.19 (q, J = 7.2 Hz, 2H), 3.43 (s, 2H), 2.53 (t, J
= 7.4 Hz, 2H), 1.54−1.64 (m, 2H), 1.33−1.24 (m, 9H), 0.88 (t, J =
6.8 Hz, 3H) ppm.
Ethyl 3-Oxodecanoate (1k).48 Compound 1k was synthesized
according to general procedure 1 using 1-bromohexane (2k, 3.36 mL,
25.0 mmol, 1.24 equiv) as starting compound. Compound was
purified by silica column chromatography (30−100% CH2Cl2 in
petroleum ether). Yield: 15% (625 mg) as a yellow oil. 1H NMR (400
MHz, CDCl3) δ 4.19 (q, J = 7.2 Hz, 2H), 3.43 (s, 2H), 2.53 (t, J = 7.4
Hz, 2H), 1.64−1.53 (m, 2H), 1.33−1.24 (m, 11H), 0.88 (t, J = 7.5
Hz, 3H) ppm.
Ethyl 3-Oxo-5-phenylpentanoate (1n).49 Compound 1n was
synthesized according to general procedure 1, using benzyl bromide
(2n, 2.90 mL, 24.4 mmol, 1.22 equiv) as starting compound.
Compound was purified by silica column chromatography (1−30%
EtOAc in petroleum ether). Yield: 20% (1.06 g) as a colorless oil. 1H
NMR (400 MHz, CDCl3) δ 7.33−7.23 (m, 2H), 7.23−7.12 (m, 3H),
4.17 (q, J = 7.2 Hz, 2H), 3.42 (s, 2H), 2.98−2.81 (m, 4H), 1.26 (t, J =
7.2 Hz, 3H) ppm.
General Procedure 2. Benzylated β-Keto Esters 4aa−na,
4bb−bq, 4eq−ev.23 LiCl (1.00 equiv) was slurried in anhydrous
THF (1 mL/mmol 1a−n) in a flame-dried round-bottom flask and
under an atmosphere of nitrogen. The desired β-keto ester 1a−n
(1.00 equiv) was added and followed by DIPEA (2.00 equiv) and the
respective benzylic halide 3a−v (1.20 equiv). The reaction mixture
was refluxed for 20 h, after which the reaction was completed as
indicated by TLC (5−10% EtOAc in petroleum ether). THF was
removed in vacuo, the crude dissolved in EtOAc (30 mL), and this
organic layer was washed with citric acid (5%, 25 mL) followed by
saturated NaHCO3 (25 mL) and brine (25 mL). The organic layer
was subsequently dried over MgSO4, and concentrated in vacuo to
afford the crude product. The crude product was purified by flash
column chromatography (5−10% EtOAc/petroleum ether) to yield
the corresponding benzylated β-keto esters 4aa−na, 4bb−bq, 4eq−
ev.
Ethyl 2-(3-Chlorobenzyl)-3-oxobutanoate (4aa).23 Com-
pound was synthesized according to general procedure 2, using the
following reagents: ethyl 3-oxobutanoate 1a (0.37 mL, 2.92 mmol,
1.20 equiv), 3-chlorobenzyl bromide 3a (0.32 mmol, 2.43 mmol, 1.00
equiv), DIPEA (0.85 mL, 4.86 mmol, 2.00 equiv), LiCl (103 mg, 2.43
mmol, 1.00 equiv), 5 mL of dry THF. Yield: 70% (433 mg) as a
colorless oil. 1H NMR: (400 MHz, CDCl3): δ 7.21−7.14 (m, 3H),
7.09−7.04 (m, 1H), 4.16 (q, J = 7.2 Hz, 2H), 3.75 (t, J = 8.0 Hz, 1H),
3.17−3.07 (m, 2H), 2.21 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H) ppm.
Ethyl 3-cyclopropyl-2-(3-chlorobenzyl)-3-oxopropanoate
(4ba).23 Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (7.56 mL, 51.2 mmol, 1.00 equiv), 3-chlorobenzyl bromide 3a
(7.06 mL, 53.8 mmol, 1.05 equiv), DIPEA (17.8 mL, 102 mmol, 2.00
equiv), LiCl (2.17 g, 51.22 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: 71% (10.2 g) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
7.21−7.l6 (m, 3H), 7.10−7.05 (m, 1H), 4.17 (qd, J = 7.2, 1.6 Hz,
2H), 3.89 (t, J = 7.6 Hz, 1H), 3.15 (dd, J = 7.2 Hz, 2H), 2.08−2.02
(m, 1H), 1.22 (t, J = 7.2 Hz, 3H), 1.11−1.01 (m, 2H), 0.98−0.88 (m,
2H) ppm.
Ethyl 2-Benzyl-3-cyclopropyl-3-oxopropanoate (4bb).24
Compound was synthesized according to general procedure 2, using
the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate 1b (0.52
mL, 3.51 mmol, 1.20 equiv), benzyl bromide 3b (0.347 mL, 2.92
mmol, 1.00 equiv), DIPEA (1.02 mL, 5.84 mmol, 2.00 equiv), LiCl
(124 mg, 2.92 mmol, 1.00 equiv), 4 mL of dry THF. Yield: 26% (105
mg) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.29−7.25 (m,
2H), 7.22−7.18 (m, 3H), 4.20−4.12 (m, 2H), 3.91 (t, J = 7.6 Hz,
1H), 3.20 (d, J = 7.6 Hz, 2H), 2.08−2.02 (m, 1H), 1.20 (t, J = 7.2 Hz,
3H), 1.06−1.03 (m, 2H), 0.94−0.84 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-2-(2-methylbenzyl)-3-oxopropanoate
(4bc). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.63 mL, 4.27 mmol, 1.20 equiv), 2-methylbenzyl chloride 3c
(0.48 mL, 3.56 mmol, 1.00 equiv), DIPEA (1.24 mL, 7.12 mmol, 2.00
equiv), LiCl (151 mg, 3.56 mmol, 1.00 equiv), 4 mL of dry THF.
Yield: 80% (742 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3)
δ 7.15−7.09 (m, 4H), 4.16 (qd, J = 7.2, 1.2 Hz, 2H), 3.91 (t, J = 7.2
Hz, 1H), 3.20 (d, J = 7.6 Hz, 2H), 2.34 (s, 3H), 2.05−2.00 (m, 1H),
1.20 (t, J = 7.2 Hz, 3H), 1.07−1.02 (m, 2H), 0.95−0.84 (m, 2H)
ppm.
Ethyl 3-Cyclopropyl-2-(2-chlorobenzyl)-3-oxopropanoate
(4bd). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.43 mL, 2.92 mmol, 1.20 equiv), 2-chlorobenzyl bromide 3d
(0.32 mL, 2.43 mmol, 1.00 equiv), DIPEA (0.85 mL, 4.86 mmol, 2.00
equiv), LiCl (103 mg, 2.43 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: 78% (532 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3)
δ 7.36−7.33 (m, 1H), 7.26−7.24 (m, 1H), 7.18−7.14 (m, 2H), 4.20−
4.08 (m, 3H), 3.37−3.22 (m, 2H), 2.10−2.03 (m, 1H), 1.21 (t, J =
7.2 Hz, 3H), 1.09−1.01 (m, 2H), 0.97−0.87 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-2-(2-methoxybenzyl)-3-oxopropa-
noate (4be). Compound was synthesized according to general
procedure 2, using the following reagents: ethyl 3-cyclopropyl-3-
oxopropanoate 1b (0.33 mL, 2.26 mmol, 1.20 equiv), 2-methox-
ybenzyl bromide50 3e (378 mg, 1.88 mmol, 1.00 equiv), DIPEA (0.66
mL, 3.76 mmol, 2.00 equiv), LiCl (79.7 mg, 1.88 mmol, 1.00 equiv), 5
mL of dry THF. Silica column chromatography in 8:1:1 petroleum
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ether:EtOAc:CH2Cl2. Yield: 36% (185 mg) as a colorless oil.
1H
NMR (400 MHz, CDCl3) δ 7.20 (td, J = 6.4, 1.6 Hz, 1H), 7.13 (dd, J
= 6.0, 1.2 Hz, 1H), 6.86−6.26 (m, 2H), 4.17−4.09 (m, 2H), 4.04 (dd,
J = 6.8, 1.6 Hz, 1H), 3.84 (s, 3H), 3.42−3.11 (m, 2H), 2.07−2.02 (m,
1H), 1.19 (t, J = 6.0 Hz, 3H), 1.05−1.02 (m, 2H), 0.92−0.85 (m,
2H) ppm.
Ethyl 3-Cyclopropyl-2-(3-methylbenzyl)-3-oxopropanoate
(4bf). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.47 mL, 3.24 mmol, 1.20 equiv), 3-methylbenzyl bromide 3f
(0.36 mL, 2.70 mmol, 1.00 equiv), DIPEA (0.94 mL, 5.40 mmol, 2.00
equiv), LiCl (114 mg, 2.70 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: 74% (521 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3)
δ 7.17 (t, J = 7.6 Hz, 1H), 7.02−6.96 (m, 3H), 4.19−4.10 (m, 2H),
3.90 (t, J = 7.6 Hz, 1H), 3.15 (d, J = 7.6 Hz, 2H), 2.30 (s, 3H), 2.07−
2.01 (m, 1H), 1.19 (t, J = 7.2 Hz, 3H), 1.04−0.99 (m, 2H), 0.93−
0.82 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-2-(3-fluorobenzyl)-3-oxopropanoate
(4bg).23 Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.550 mL, 3.73 mmol, 1.31 equiv), 3-fluorobenzyl bromide 3g
(0.350 mL, 2.85 mmol, 1.00 equiv), DIPEA (0.940 mL, 5.39 mmol,
1.89 equiv), LiCl (0.140 g, 2.70 mmol, 0.947 equiv), 5 mL of dry
THF. Yield: 100% (770 mg) as a yellow oil. 1H NMR (400 MHz,
CDCl3) δ 7.26−7.16 (m, 1H), 6.97 (d, J = 8.0 Hz, 1H), 6.94−6.84
(m, 2H), 4.19−4.11 (m, 2H), 3.92 (t, J = 7.6 Hz, 1H), 3.18 (dd, J =
7.6, 1.6 Hz, 2H), 2.10−2.04 (m, 1H), 1.20 (t, J = 7.2 Hz, 3H), 1.07−
0.98 (m, 2H), 0.93−0.83 (m, 2H) ppm.
Ethyl 2-(3-Bromobenzyl)-3-cyclopropyl-3-oxopropanoate
(4bh). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.35 mL, 2.40 mmol, 1.20 equiv), 3-bromobenzyl bromide 3h
(500 mg, 2.00 mmol, 1.00 equiv), DIPEA (0.70 mL, 4.00 mmol, 2.00
equiv), LiCl (85 mg, 2.00 mmol, 1.00 equiv), 5 mL of dry THF. Yield:
47% (303 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
7.36−7.32 (m, 2H), 7.17−7.10 (m, 2H), 4.17 (q, J = 7.2 Hz, 2H),
3.89 (t, J = 7.2 Hz, 1H), 3.15 (d, J = 8.0 Hz, 2H), 2.08−2.01 (m, 1H),
1.22 (t, J = 7.2 Hz, 3H), 1.11−1.01 (m, 2H), 0.98−0.86 (m, 2H)
ppm.
Ethyl 3-Cyclopropyl-2-(3-iodobenzyl)-3-oxopropanoate
(4bi). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.550 mL, 3.73 mmol, 1.38 equiv), 3-iodobenzyl bromide 3i
(0.802 g, 2.70 mmol, 1.00 equiv), DIPEA (0.940 mL, 5.39 mmol, 2.00
equiv), LiCl (0.150 g, 2.70 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: quantitative (1.28 g) as a yellow oil. 1H NMR (400 MHz,
CDCl3) δ 7.55−7.51 (m, 2H), 7.15 (d, J = 7.6 Hz, 1H), 6.99 (t, J =
7.6 Hz, 1H), 4.16 (qd, J = 7.2, 1.6 Hz, 2H), 3.87 (t, J = 7.2 Hz, 1H),
3.11 (dd, J = 8.0, 2.0 Hz, 2H), 2.06−2.00 (m, 1H), 1.20 (t, J = 6.8 Hz,
3H), 1.11−1.00 (m, 2H), 0.98−0.81 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-2-(3-methoxybenzyl)-3-oxopropa-
noate (4bj).51 Compound was synthesized according to general
procedure 2, using the following reagents: ethyl 3-cyclopropyl-3-
oxopropanoate 1b (0.44 mL, 3.00 mmol, 1.20 equiv), 3-methox-
ybenzyl bromide 3j (0.35 mL, 2.50 mmol, 1.00 equiv), DIPEA (0.87
mL, 5.00 mmol, 2.00 equiv), LiCl (106 mg, 2.50 mmol, 1.00 equiv), 5
mL of dry THF. Silica column chromatography in 8:1:1 petroleum
ether:EtOAc:CH2Cl2. Yield: 42% (294 mg) as a colorless oil.
1H
NMR (400 MHz, CDCl3) δ 7.19 (td, J = 7.2 Hz, 1.2 Hz, 1H), 6.79−
6.74 (m, 3H), 4.21−4.13 (m, 2H), 3.91 (t, J = 7.6 Hz, 1H), 3.78 (s,
3H), 3.17 (d, J = 7.6 Hz, 2H), 2.08−2.02 (m, 1H), 1.22 (t, J = 7.2 Hz,
3H), 1.06−1.01 (m, 2H), 0.96−0.85 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-3-oxo-2-(3-(trifluoromethyl)benzyl)-
propanoate (4bk).24 Compound was synthesized according to
general procedure 2, using the following reagents: ethyl 3-cyclopropyl-
3-oxopropanoate 1b (0.37 mL, 2.51 mmol, 1.20 equiv), 3-
(trifluoromethyl)benzyl bromide 3k (0.32 mL, 2.09 mmol, 1.00
equiv), DIPEA (0.73 mL, 4.18 mmol, 2.00 equiv), LiCl (89 mg, 2.09
mmol, 1.00 equiv), 5 mL of dry THF. Yield: 31% (214 mg) as a
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.50−7.44 (m, 2H),
7.42−7.38 (m, 2H), 4.17 (q, J = 6.8 Hz, 2H), 3.92 (t, J = 8.0 Hz, 1H),
3.25 (d, J = 7.2 Hz, 2H), 2.10−2.02 (m, 1H), 1.21 (t, J = 7.2 Hz, 3H),
1.12−1.01 (m, 2H), 0.99−0.86 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-2-(4-methylbenzyl)-3-oxopropanoate
(4bl). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.48 mL, 3.24 mmol, 1.20 equiv), 4-methylbenzyl bromide 3l
(500 mg, 2.70 mmol, 1.00 equiv), DIPEA (0.94 mL, 5.40 mmol, 2.00
equiv), LiCl (114 mg, 2.70 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: 74% (521 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3)
δ 7.08 (s, 4H), 4.22−4.09 (m, 2H), 3.88 (t, J = 7.6 Hz, 1H), 3.15 (d, J
= 7.6 Hz, 2H), 2.30 (s, 3H), 2.07−2.02 (m, 1H), 1.21 (t, J = 7.2 Hz,
3H), 1.07−1.02 (m, 2H), 0.96−0.83 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-2-(4-fluorobenzyl)-3-oxopropanoate
(4bm). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.890 mL, 6.04 mmol, 1.14 equiv), 1-(bromomethyl)-4-
fluorobenzene 3m (1.57 g, 5.29 mmol, 1.00 equiv), DIPEA (1.05
mL, 6.00 mmol, 1.13 equiv), LiCl (0.130 g, 3.00 mmol, 0.58 equiv), 5
mL of dry THF. Yield: 56% (780 mg) as a yellow oil. 1H NMR (400
MHz, CDCl3) δ 7.18−7.12 (m, 2H), 6.96 (tt, J = 8.8, 2.0 Hz, 2H),
4.22−4.10 (m, 2H), 3.87 (t, J = 8.0 Hz, 1H), 3.16 (d, J = 7.6 Hz, 2H),
2.08−2.00 (m, 1H), 1.21 (t, J = 7.2 Hz, 3H), 1.09- 0.99 (m, 2H),
0.97−0.84 (m, 2H) ppm.
Ethyl 2-(4-Chlorobenzyl)-3-cyclopropyl-3-oxopropanoate
(4bn). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.43 mL, 2.92 mmol, 1.20 equiv), 4-chlorobenzyl bromide 3n
(500 mg, 2.43 mmol, 1.00 equiv), DIPEA (0.85 mL, 4.86 mmol, 2.00
equiv), LiCl (103 mg, 2.43 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: 66% (451 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3)
δ 7.24 (dt J = 8.8, 2.0 Hz,, 2H), 7.13 (dt, J = 8.4, 2.0 Hz, 2H), 4.21−
4.11 (m, 2H), 3.87 (dd, J = 8.0, 0.8 Hz, 1H), 3.15 (dd, J = 6.8, 1.2 Hz,
2H), 2.08−2.01 (m, 1H), 1.21 (t, J = 7.2 Hz, 3H), 1.09−1.01 (m,
2H), 0.97−0.86 (m, 2H) ppm.
Ethyl 2-(4-Bromobenzyl)-3-cyclopropyl-3-oxopropanoate
(4bo). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopropyl-3-oxopropanoate
1b (0.880 mL, 5.97 mmol, 1.49 equiv), 1-(bromomethyl)-4-
bromobenzene 3o (1.00 g, 4.00 mmol, 1.00 equiv), DIPEA (1.39
mL, 8.00 mmol, 2.00 equiv), LiCl (0.170 g, 4.00 mmol, 1.00 equiv), 5
mL of dry THF. Yield: 67% (0.880 g) as a yellow oil. 1H NMR (400
MHz, CDCl3) δ 7.39 (d, J = 8.4 Hz, 2H), 7.07 (d, J = 8.4 Hz, 2H),
4.22−4.10 (m, 2H), 3.87 (t, J = 8.0 Hz, 1H), 3.14 (d, J = 8.2 Hz, 2H),
2.08−1.96 (m, 1H), 1.22 (t, J = 7.2 Hz, 3H), 1.10−0.99 (m, 2H),
0.99−0.85 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-2-(4-methoxybenzyl)-3-oxopropa-
noate (4bp). Compound was synthesized according to general
procedure 2, using the following reagents: ethyl 3-cyclopropyl-3-
oxopropanoate 1b (0.57 mL, 3.83 mmol, 1.20 equiv), 4-methox-
ybenzyl bromide 3p (0.46 mL, 3.19 mmol, 1.00 equiv), DIPEA (1.11
mL, 6.38 mmol, 2.00 equiv), LiCl (135 mg, 3.19 mmol, 1.00 equiv), 5
mL of dry THF. Silica column chromatography in 7:1:2 petroleum
ether:EtOAc:CH2Cl2. Yield: 52% (454 mg) as a colorless oil.
1H
NMR (400 MHz, CDCl3) δ 7.10 (dt, J = 8.8, 2.0 Hz, 2H), 6.81 (dt, J
= 8.8, 2.4 Hz, 2H), 4.20−4.10 (m, 2H), 3.86 (t, J = 7.6 Hz, 1H), 3.78
(s, 3H), 3.13 (d, J = 7.6 Hz, 2H), 2.07−2.01 (m, 1H), 1.21 (t, J = 7.2
Hz, 3H), 1.08−1.01 (m, 2H), 0.95−0.83 (m, 2H) ppm.
Ethyl 3-Cyclopropyl-2-(3,4-dichlorobenzyl)-3-oxopropa-
noate (4bq).23 Compound was synthesized according to general
procedure 2, using the following reagents: ethyl 3-cyclopropyl-3-
oxopropanoate 1b (0.60 mL, 4.06 mmol, 1.00 equiv), 3,4-
dichlorobenzyl bromide 3q (0.62 mL, 4.27 mmol, 1.05 equiv),
DIPEA (1.42 mL, 8.13 mmol, 2.00 equiv), LiCl (172 mg, 4.06 mmol,
1.00 equiv), 5 mL of dry THF. Yield: 39% (493 mg) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 8.4 Hz, 1H), 7.30 (d, J =
1.6 Hz, 1H), 7.03 (dd, J = 8.4, 2.0 Hz, 1H), 4.22−4.12 (m, 2H), 3.87
(t, J = 7.6 Hz, 1H), 3.18−3.09 (m, 2H), 2.09−2.02 (m, 1H), 1.23 (t, J
= 7.2 Hz, 3H), 1.09−1.01 (m, 2H), 0.95−0.85 (m, 2H) ppm.
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Ethyl 2-(3-Chlorobenzyl)-3-oxopentanoate (4ca).52 Com-
pound was synthesized according to general procedure 2, using the
following reagents: ethyl 3-oxopentanoate 1c (0.42 mL, 2.92 mmol,
1.20 equiv), 3-chlorobenzyl bromide 3a (0.32 mL, 2.43 mmol, 1.00
equiv), NaH (117 mg, 4.86 mmol, 2.00 equiv), 5 mL of dry THF.
Yield: 52% (340 mg) as a colorless oil. 1H NMR (500 MHz, CDCl3):
δ 7.20−7.14 (m, 3H), 7.09−7.03 (m, 1H), 4.15 (qd, J = 7.5, 0.8 Hz,
2H), 3.76 (t, J = 7.5 Hz, 1H), 3.17−3.08 (m, 2H), 2.60 (dqd, J = 18.0,
7.0, 1.0 Hz, 1H), 2.37 (dqd, J = 18.5, 7.0, 0.5 Hz, 1H), 1.20 (td, J =
7.0, 1.0 Hz, 3H), 1.01 (td, J = 7.5, 1.0 Hz, 3H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-oxohexanoate (4da).23 Com-
pound was synthesized according to general procedure 2, using the
following reagents: ethyl 3-oxohexanoate 1d (0.46 mL, 2.92 mmol,
1.20 equiv), 2.43 mmol of 3-chlorobenzyl bromide 3a, DIPEA (0.85
mmol, 4.86 mmol, 2.00 equiv), LiCl (103 mg, 2.43 mmol, 1.00 equiv),
5 mL of dry THF. Yield: 76% (522 mg) as a colorless oil. 1H NMR
(400 MHz, CDCl3): δ 7.22−7.14 (m, 3H), 7.08−7.04 (m, 1H), 4.15
(q, J = 7.2 Hz, 2H), 3.75 (t, J = 7.6 Hz, 1H), 3.18−3.07 (m, 2H), 2.54
(dt, J = 17.6, 7.2 Hz, 1H), 2.35 (dt, J = 17.2, 7.2 Hz, 1H), 1.57 (sextet,
J = 7.2 Hz, 2H), 1.21 (t, J = 7.2 Hz, 3H), 0.85 (t, J = 7.6 Hz, 3H)
ppm.
Ethyl 2-(3-Chlorobenzyl)-4-methyl-3-oxopentanoate
(4ea).23 Compound was synthesized according to general procedure
2, using the following reagents: ethyl 4-methyl-3-oxopentanoate 1e
(0.51 mL, 3.16 mmol, 1.20 equiv), 3-chlorobenzyl bromide 3a (0.35
mL, 2.63 mmol, 1.00 equiv), DIPEA (0.95 mL, 5.26 mmol, 2.00
equiv), LiCl (111 mg, 2.63 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: 86% (640 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3):
δ 7.20−7.14 (m, 3H), 7.07−7.04 (m, 1H), 4.14 (qd, J = 7.2, 0.8 Hz,
2H), 3.91 (t, J = 7.6 Hz, 1H), 3.17−3.07 (m, 2H), 2.66 (septet, J =
6.8 Hz, 1H), 1.21 (t, J = 7.2 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H), 0.91
(d, J = 7.2 Hz, 3H) ppm.
Ethyl 2-(3,4-Dichlorobenzyl)-4-methyl-3-oxopentanoate
(4eq).24 Compound was synthesized according to general procedure
2, using the following reagents: ethyl 4-methyl-3-oxopentanoate 1e
(5.00 mL, 31.0 mmol, 1.00 equiv), 3,4-dichlorobenzyl bromide 3q
(5.41 mL, 37.2 mmol, 1.20 equiv), DIPEA (10.8 mL, 62.0 mmol, 2.00
equiv), LiCl (1.31 g, 30.9 mmol, 1.00 equiv), 50 mL of dry THF.
Yield: 33% (3.20 g) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ
7.33 (d, J = 8.4 Hz, 1H), 7.29−7.25 (m, 1H), 7.01 (dd, J = 8.0, 2.0
Hz, 1H), 4.15 (qd, J = 7.2, 1.6 Hz, 2H), 3.89 (t, J = 7.6 Hz, 1H),
3.16−3.04 (m, 2H), 2.69 (heptet, J = 6.8 Hz, 1H), 1.22 (t, J = 7.2 Hz,
3H), 1.07 (d, J = 6.4 Hz, 3H), 0.93 (d, J = 7.2 Hz, 3H) ppm.
Ethyl 2-(2,3-Dichlorobenzyl)-4-methyl-3-oxopentanoate
(4er). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 4-methyl-3-oxopentanoate 1e
(0.670 mL, 4.61 mmol, 1.00 equiv), 2,3-dichlorobenzyl bromide 3r
(1.00 g, 4.17 mmol, 0.90 equiv), DIPEA (1.45 mL, 8.34 mmol, 1.81
equiv), LiCl (180 mg, 0.90 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: 8% (110 mg) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ
7.34 (dd, J = 7.6, 1.6 Hz, 1H), 7.15 (dd, J = 7.6, 1.6 Hz, 1H), 7.09 (t, J
= 7.6 Hz, 1H), 4.20−4.03 (m, 3H), 3.34−3.22 (m, 2H), 2.71 (heptet,
J = 6.8 Hz, 1H), 1.19 (t, J = 7.2 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H),
0.90 (d, J = 6.8 Hz, 3H) ppm.
Ethyl 2-(2,5-Dichlorobenzyl)-4-methyl-3-oxopentanoate
(4es). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 4-methyl-3-oxopentanoate 1e
(0.204 mL, 1.39 mmol, 1.00 equiv), 2,5-dichlorobenzyl bromide 3s
(500 mg, 2.08 mmol, 1.5 equiv), DIPEA (0.242 mL, 1.39 mmol, 1.00
equiv), LiCl (60 mg, 1.39 mmol, 1.00 equiv), 5 mL of dry THF. Yield:
71% (315 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.27
(d, J = 8.8 Hz, 1H), 7.22 (d, J = 2.4 Hz, 1H), 7.15 (dd, J = 8.4, 2.4 Hz,
1H), 4.18−4.12 (m, 2H), 4.10 (t, J = 7.2 Hz, 1H), 3.26−3.16(m, 2H),
2.73 (heptet, J = 6.8 Hz, 1H), 1.22 (t, J = 7.2 Hz, 3H), 1.08 (d, J = 6.8
Hz, 3H), 0.93 (d, J = 7.2 Hz, 3H) ppm.
Ethyl 2-(3,5-Dichlorobenzyl)-4-methyl-3-oxopentanoate
(4et).24 Compound was synthesized according to general procedure
2, using the following reagents: ethyl 4-methyl-3-oxopentanoate 1e
(0.480 mL, 3.30 mmol, 1.00 equiv), 3,5-dichlorobenzyl bromide 3t
(0.440 mL, 3.12 mmol, 1.00 equiv), DIPEA (1.05 mL, 6.00 mmol,
1.82 equiv), LiCl (0.310 g, 3.00 mmol, 0.91 equiv), 5 mL of dry THF.
Yield: 16% (150 mg) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ
7.13 (t, J = 2.0 Hz, 1H), 6.99 (d, J = 2.0 Hz, 2H), 4.08 (q, J = 7.2 Hz,
2H), 3.81 (t, J = 7.6 Hz, 1H), 3.07−2.97 (m, 2H), 2.63 (heptet, J =
6.8 Hz, 1H), 1.15 (t, J = 7.2 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H), 0.87
(d, J = 6.8 Hz, 3H) ppm.
Ethyl 2-(3,5-Dibromobenzyl)-4-methyl-3-oxopentanoate
(4eu). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 4-methyl-3-oxopentanoate 1e
(0.480 mL, 3.30 mmol, 1.00 equiv), 3,5-dibromobenzyl bromide 3u
(1.04 g, 3.16 mmol, 0.958 equiv), DIPEA (1.05 mL, 6.00 mmol, 1.82
equiv), LiCl (0.130 g, 3.00 mmol, 0.909 equiv), 5 mL of dry. THF.
Yield: 29% (0.350 g) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ
7.27 (s, 3H), 4.15 (q, J = 7.2 Hz, 2H), 3.87 (t, J = 7.2 Hz, 1H), 3.13−
3.05 (m, 2H), 2.70 (heptet, J = 6.8 Hz, 1H), 1.24 (t, J = 6.4 Hz, 3H),
1.08 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H) ppm.
Ethyl 2-(3-Bromo-4-chlorobenzyl)-4-methyl-3-oxopenta-
noate (4ev). Compound was synthesized according to general
procedure 2, using the following reagents: ethyl 4-methyl-3-
oxopentanoate 1e (0.480 mL, 3.30 mmol, 1.00 equiv), 3-bromo-4-
chlorobenzyl bromide 3v (0.900 g, 3.16 mmol, 0.958 equiv), DIPEA
(1.05 mL, 6.00 mmol, 1.82 equiv), LiCl (0.130 g, 3.00 mmol, 0.909
equiv), 5 mL of dry THF. Yield: 34% (0.360 g) as a yellow oil. 1H
NMR (400 MHz, CDCl3) δ 7.44 (d, J = 2.0 Hz, 1H), 7.33 (d, J = 8.0
Hz, 1H), 7.06 (dd, J = 8.0, 2.0 Hz, 1H), 4.15 (qd, J = 7.2, 1.6 Hz,
2H), 3.88 (t, J = 7.6 Hz, 1H), 3.14−3.04 (m, 2H), 2.69 (heptet, J =
6.8 Hz, 1H), 1.22 (t, J = 7.2 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 0.94
(d, J = 6.8 Hz, 3H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-oxoheptanoate (4fa). Compound
was synthesized according to general procedure 2, using the following
reagents: ethyl 3-oxoheptanoate 1f (0.47 g, 2.72 mmol, 1.00 equiv), 3-
chlorobenzyl bromide 3a (0.33 mL, 2.51 mmol, 0.922 equiv), DIPEA
(1.05 mL, 6.00 mmol, 2.21 equiv), LiCl (0.130 g, 3.00 mmol, 1.10
equiv), 5 mL of dry THF. Yield: 67% (0.550 g) as a colorless oil. 1H
NMR (400 MHz, CDCl3) δ 7.20−7.15 (m, 3H), 7.07−7.03 (m, 1H),
7.17−4.10 (m, 2H), 3.75 (t, J = 7.6 Hz, 1H), 3.16−3.06 (m, 2H),
2.55 (dt, J = 17.2, 7.2 Hz, 1H), 2.35 (dt, J = 17.6, 7.2 Hz, 1H), 1.50
(pentet, J = 7.6 Hz, 2H), 1.28−1.19 (m, 5H), 0.85 (t, J = 7.2 Hz, 3H)
ppm.
Ethyl 2-(3-Chlorobenzyl)-5-ethyl-3-oxoheptanoate (4ga).
Compound was synthesized according to general procedure 2, using
the following reagents: ethyl 5-ethyl-3-oxoheptanoate 1g (0.600 g,
3.00 mmol, 1.00 equiv), 3-chlorobenzyl bromide 3a (0.470 mL, 3.57
mmol, 1.19 equiv), DIPEA (1.05 mL, 6.00 mmol, 2.00 equiv), LiCl
(0.130 g, 3.00 mmol, 1.00 equiv), 5 mL of dry THF. Yield: 31%
(0.300 g) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.20−7.14
(m, 3H), 7.06−7.05 (m, 1H), 4.18−4.12 (m, 2H), 3.75 (t, J = 7.6 Hz,
1H), 3.17−3.06 (m, 2H), 2.45 (dd, J = 17.2, 6.8 Hz, 1H), 2.29 (dd, J
= 17.2, 6.0 Hz, 1H), 1.76 (heptet, J = 6.4 Hz, 1H), 1.30−1.17 (m,
7H), 0.78 (t, J = 7.6 Hz, 6H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-oxooctanoate (4ha). Compound
was synthesized according to general procedure 2, using the following
reagents: ethyl 3-oxooctanoate 1h (0.560 g, 3.01 mmol, 1.00 equiv),
3-chlorobenzyl bromide 3a (0.470 mL, 3.57 mmol, 1.18 equiv),
DIPEA (1.05 mL, 6.00 mmol, 1.99 equiv), LiCl (0.130 g, 3.00 mmol,
1.00 equiv), 5 mL of dry THF. Yield: 21% (0.197 g) as a yellow oil.
1H NMR (400 MHz, CDCl3) δ 7.22−7.15 (m, 3H), 7.07−7.04 (m,
1H), 4.15 (q, J = 7.2 Hz, 2H), 3.75 (t, J = 7.6 Hz, 1H), 3.17−3.07 (m,
2H), 2.54 (dt, J = 17.2, 7.2 Hz, 1H), 2.36 (dt, J = 17.2, 7.2 Hz, 1H),
1.52 (pentet, J = 7.4 Hz, 2H), 1.31−1.13 (m, 7H), 0.86 (t, J = 7.2 Hz,
3H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-cyclopentyl-3-oxopropanoate
(4ia).23 Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-cyclopentyl-3-oxopropanoate
1i (0.376 g, 2.04 mmol, 1.00 equiv), 3-chlorobenzyl bromide 3a
(0.240 mL, 1.83 mmol, 0.888 equiv), DIPEA (0.530 mL, 3.03 mmol,
1.47 equiv), LiCl (0.067 g, 1.57 mmol, 0.772 equiv), 5 mL of dry
THF. Silica column chromatography (20−50% CH2Cl2/petroleum
ether). Yield: 85% (0.483 g) as a colorless oil. 1H NMR (400 MHz,
CDCl3) δ 7.20−7.15 (m, 3H), 7.08−7.02 (m, 1H), 4.13 (q, J = 7.2
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.9b00742
J. Med. Chem. 2019, 62, 11035−11053
11046
Hz, 2H), 3.85 (t, J = 7.6 Hz, 1H), 3.15−3.05 (m, 2H), 2.94 (pentet, J
= 8.0 Hz, 1H), 1.87−1.35 (m, 8H), 1.20 (t, J = 7.2 Hz, 3H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-oxononanoate (4ja). Compound
was synthesized according to general procedure 2, using the following
reagents: ethyl 3-oxononanoate 1j (0.601 g, 3.00 mmol, 1.00 equiv),
3-chlorobenzyl bromide 3a (0.325 mL, 2.48 mmol, 0.825 equiv),
DIPEA (1.05 mL, 6.00 mmol, 2.00 equiv), LiCl (0.130 g, 3.00 mmol,
1.00 equiv), 5 mL of dry THF. Yield: 97% (0.780 g) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 7.20−7.15 (m, 3H), 7.07−7.01 (m,
1H), 4.14 (q, J = 6.8 Hz, 2H), 3.75 (t, J = 7.6 Hz, 1H), 3.17−3.06 (m,
2H), 2.53 (dt, J = 17.6, 7.2 Hz, 1H), 2.35 (dt, J = 17.6, 7.2 Hz, 1H),
1.50 (pentet, J = 7.2 Hz, 2H), 1.30−1.15 (m, 9H), 0.85 (t, J = 7.2 Hz,
3H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-oxodecanoate (4ka). Compound
was synthesized according to general procedure 2, using the following
reagents: ethyl 3-oxodecanoate 1k (0.650 g, 3.03 mmol, 1.00 equiv),
3-chlorobenzyl bromide 3a (0.475 mL, 3.60 mmol, 1.20 equiv),
DIPEA (1.05 mL, 6.00 mmol, 2.00 equiv), LiCl (0.128 g, 3.00 mmol,
1.00 equiv), 5 mL of dry THF. Yield: 50% (0.511 g) as a yellow oil.
1H NMR (400 MHz, CDCl3) δ 7.21−7.16 (m, 3H), 7.07−7.04 (m,
1H), 4.15 (q, J = 7.2 Hz, 2H), 3.75 (t, J = 7.6 Hz, 1H), 3.18−3.06 (m,
2H), 2.54 (dt, J = 17.6, 7.2 Hz, 1H), 2.36 (dt, J = 17.6, 7.6 Hz, 1H),
1.51 (pentet, J = 6.8 Hz, 2H), 1.31−1.17 (m, 11H), 0.87 (t, J = 6.8
Hz, 3H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-oxo-3-phenylpropanoate
(4la).23 Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-oxo-3-phenylpropanoate 1l
(0.498 mL, 2.92 mmol, 1.20 equiv), 3-chlorobenzyl bromide 3a
(0.320 mL, 2.43 mmol, 1.00 equiv), DIPEA (0.847 mL, 4.86, 2.00
equiv), LiCl (103 mg; 2.43 mmol, 1.00 equiv), 5 mL of dry THF.
Yield: 85% (686 mg) as a colorless oil. 1H NMR (400 MHz, CDCl3):
δ 7.92 (dd, J = 8.0, 0.8, 2H), 7.46 (td, J = 7.6, 1.2 Hz, 1H), 7.35 (t, J =
7.6 Hz, 2H), 7.20 (s, 1H), 7.10−7.05 (m, 3H), 4.62 (t, J = 7.2 Hz,
1H), 4.05−3.95 (m, 2H), 3.31−3.20 (m, 2H), 1.01 (t, J = 7.2, 0.8 Hz,
3H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-oxo-3-(p-tolyl)propanoate
(4ma). Compound was synthesized according to general procedure
2, using the following reagents: ethyl 3-oxo-3-(p-tolyl)propanoate 1m
(2.30 g, 11.15 mmol, 1.00 equiv), 3-chlorobenzyl bromide 3a (2.29
mL, 11.15 mmol, 1.00 equiv), DIPEA (3.88 mL, 22.3 mmol, 2.00
equiv), LiCl (473 mg; 11.15 mmol, 1.00 equiv), 30 mL of dry THF.
Yield: 86% (3.18 g) as a white solid. 1H NMR (400 MHz, CDCl3): δ
7.87 (d, J = 8.0 Hz, 2H), 7.28−7.22 (m, 3H), 7.19−7.14 (m, 2H),
7.12−7.09 (m, 1H), 4.57 (t, J = 7.6 Hz, 1H), 4.13−4.05 (m, 2H),
3.33−3.23 (m, 2H), 2.41 (s, 3H), 1.12 (t, J = 7.2 Hz, 3H) ppm.
Ethyl 2-(3-Chlorobenzyl)-3-oxo-5-phenylpentanoate (4na).
Compound was synthesized according to general procedure 2, using
the following reagents: ethyl 3-oxo-5-phenylpentanoate 1n (0.661 g,
3.00 mmol, 1.00 equiv), 3-chlorobenzyl bromide 3a (0.475 mL, 3.65
mmol, 1.20 equiv), DIPEA (1.05 mL, 6.00 mmol, 2.00 equiv), LiCl
(0.128 g, 3.00 mmol, 1.00 equiv), 5 mL of dry THF. Yield: 67%
(0.690 g) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.32−7.26
(m, 2H), 7.24−7.19 (m, 3H), 7.16 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2
Hz, 2H), 3.75 (t, J = 7.6 Hz, 1H), 3.13 (d, J = 7.6 Hz, 2H), 2.99−2.85
(m, 3H), 2.75−2.67 (m, 1H), 1.20 (t, J = 7.2 Hz, 3H) ppm.
Procedure for the Synthesis of 6-(3-Chlorobenzyl)-5-
cyclopropyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one (6).23,24
In a sealed microwave tube 3-amino-1,2,4-triazole 5a (66 mg, 0.78
mmol, 1.1 equiv), 4ba (200 mg, 0.71 mmol, 1.00 equiv), and H3PO4
(96 μL, 1.42 mmol, 2.00 equiv) were heated at 170 °C in 1 mL of
EtOH in the microwave for 10 h. The reaction mixture was poured in
water (30 mL), the pH was adjusted to pH = 12 (1 M NaOH aq),
and the organics were extracted with EtOAc (3 × 30 mL). The
combined extracts were dried over MgSO4 and the solvents
evaporated in vacuo, resulting in 165 mg of crude mixture. The
pure product was obtained by column chromatography (5% CH3OH
in CH2Cl2) followed by prep HPLC gradient 10−90% CH3CN/water
+ 0.1%TFA yielding 4% (9 mg) as a white solid. 1H NMR (400 MHz,
CDCl3): δ 8.14 (s, 1H), 7.28−7.25 (m, 1H), 7.22−7.15 (m, 3H),
7.17−7.08 (m, 3H), 4.16 (s, 2H), 2.22−2.13 (m, 1H), 1.36−1.30 (m,
2H), 1.20−1.15 (m, 2H) ppm. LC−MS (ESI) m/z calcd for
C15H13ClN4O [M + H]
+ 301.09, found 301.1. HPLC: 6.566 min,
purity 97%.
Procedure for the Synthesis of 6-(3-Chlorobenzyl)-5-cyclo-
propyl-2-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one (7).
In a sealed microwave tube 3-amino-5-methyl-1,2,4-triazole 5b (126
mg, 1.28 mmol, 1.2 equiv), 4ba (300 mg, 1.07 mmol, 1.0 equiv), and
p-toluenesulfonic acid monohydrate (102 mg, 0.53 mmol, 0.5 equiv)
were heated for 30 min at 180 °C in the microwave. As visualized by
TLC, 4ba was consumed and mainly one product was formed (Rf 0.5
in 5% CH3OH in CH2Cl2). The crude product was purified by
column chromatography (3% CH3OH in CH2Cl2) yielding 31% (96
mg) as a white solid. 1H NMR (400 MHz, CDCl3 + drop MeOD): δ
7.23 (s, 1H), 7.21−7.13 (m, 3H), 6.26 (br s, 2H), 4.11 (s, 2H), 2.47
(s, 2H), 2.05−1.96 (m, 1H), 1.14−1.07 (m, 2H), 1.05−1.01 (m, 2H)
ppm. LC−MS (ESI) m/z calcd for C16H15ClN4O [M + H]+ 315.10,
found 315.1. HPLC: 6.826 min, purity 96%.
General Procedure 3. Triazolopyrimidinones 8−43.23 The
synthesis of compounds 8−43 was according to the following
procedure: In a microwave tube a mixture of the corresponding
benzylated β-keto ester 4aa−na, 4bb−bq, 4eq−ev (1.00 equiv),
triazole 5c (2.00 equiv) and 1-butyl-3-methylimidazolium hexafluor-
ophosphate (BMIM-PF6, 1 mL or 6.00 equiv) was heated at 200 °C
in a microwave reactor for an hour. Afterward, the reaction was
allowed to cool to room temperature and stirred in a mixture of
CH2Cl2 (30 mL), H2O (10 mL), and 5−10% aqueous citric acid (1
mL) for 20−30 min. The resulting mixture was filtered over a glass
filter, and the residue was washed with hot methanol. Finally, the
precipitate was collected and dried in vacuo to yield the pure
compounds.
2-Amino-6-(3-chlorobenzyl)-5-cyclopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (8).23 Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (216 mg, 2.18 mmol, 2.00 equiv), 4ba
(306 mg, 1.09 mmol, 1.00 equiv), and BMIM-PF6 (1.35 mL, 6.54
mmol, 6.00 equiv). Yield: 36% (125 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.16 (br s, 1H), 7.35−7.24 (m,2H), 7.24−
7.14 (m, 2H), 6.24 (br s, 2H), 3.96 (s, 2H), 2.14−2.01 (m, 1H),
1.07−0.94 (m, 2H), 0.94−0.81 (m, 2H) ppm. LC−MS (ESI) m/z
calcd for C15H14ClN5O [M + H]
+ 316.10, found 316.13. HPLC:
6.350 min, purity 98%.
2-Amino-6-benzyl-5-cyclopropyl[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (9). Compound was synthesized according to
general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (276 mg, 2.84 mmol, 2.00 equiv), 4bb (350 mg, 1.42
mmol, 1.00 equiv) and BMIM-PF6 (1.75 mL, 8.52 mmol, 6.00 equiv).
Yield: 26% (105 mg) as a white solid. 1H NMR (400 MHz, DMSO):
δ 12.11 (br s, 1H), 7.26−7.20 (m, 4H), 7.17−7.10 (m, 1H), 6.20 (br
s, 2H), 3.96 (s, 2H), 2.10−2.03 (m, 1H), 1.04−0.95 (m, 2H), 0.94−
0.88 (m, 2H) ppm. LC−MS (ESI) m/z calcd for C15H15N5O [M +
H]+ 282.14, found 282.13. HPLC: 5.655 min, purity 97%.
2-Amino-5-cyclopropyl-6-(2-methylbenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (10). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (190 mg, 1.96 mmol, 2.00 equiv), 4bc
(255 mg, 0.98 mmol, 1.00 equiv), and BMIM-PF6 (1.21 mL, 5.88
mmol, 6.00 equiv). Yield: 32% (93 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.17 (br s, 1H), 7.15 (d, J = 6.8 Hz, 1H),
7.08−6.99 (m, 2H), 6.81 (d, J = 6.8 Hz, 1H), 6.21 (br s, 2H), 3.86 (s,
2H), 2.36 (s, 3H), 1.90−1.81 (m, 1H), 1.04−0.94 (m, 2H), 0.88−
0.81 (m, 2H) ppm. LC−MS (ESI) m/z calcd for C16H17N5O [M +
H]+ 296.15, found 296.13. HPLC: 6.074 min, purity 98%.
2-Amino-6-(2-chlorobenzyl)-5-cyclopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (11). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (173 mg, 1.78 mmol, 2.00 equiv), 4bd
(250 mg, 0.89 mmol, 1.00 equiv), and BMIM-PF6 (1.01 mL, 5.34
mmol, 6.00 equiv). Yield: 37% (104 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.14 (br s, 1H), 7.47−7.42 (m, 1H), 7.24−
7.17 (m, 2H), 7.01−6.96 (m, 1H), 6.20 (br s, 2H), 4.00 (s, 2H),
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1.90−1.80 (m, 1H), 0.99−0.93 (m, 2H), 0.89−0.80 (m, 2H) ppm.
LC−MS (ESI) m/z calcd for C15H14ClN5O [M + H]+ 316.10, found
316.13. HPLC: 6.411 min, purity 95%.
2-Amino-5-cyclopropyl-6-(2-methoxybenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (12). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (130 mg, 1.34 mmol, 2.00 equiv), 4be
(185 mg, 0.67 mmol, 1.00 equiv), and BMIM-PF6 (0.83 mL, 4.02
mmol, 6.00 equiv). Yield: 43% (89 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.11 (br s, 1H), 7.15 (t, J = 6.0 Hz, 1H), 6.95
(d, J = 6.4 Hz, 1H), 6.86 (d, J = 5.6 Hz, 1H), 6.78 (t, J = 5.6 Hz, 1H),
6.18 (br s, 2H), 3.86 (s, 2H), 3.83 (s, 3H), 1.98−1.86 (m, 1H), 1.03−
0.91 (m, 2H), 0.90−0.79 (m, 2H) ppm. LC−MS (ESI) m/z calcd for
C16H17N5O2 [M + H]
+ 312.15, found 312.2. HPLC: 5.832 min,
purity 98%.
2-Amino-5-cyclopropyl-6-(3-methylbenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (13). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (216 mg, 2.22 mmol, 2.00 equiv), 4bf
(289 mg, 1.11 mmol, 1.00 equiv), and BMIM-PF6 (1.37 mL, 6.66
mmol, 6.00 equiv). Yield: 35% (114 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 11.98 (br s, 1H), 7.12 (t, J = 7.6 Hz, 1H), 7.04
(s, 1H), 7.01 (d, J = 7.2 Hz, 1H), 6.95 (d, J = 7.2 Hz, 1H), 6.17 (br s,
2H), 3.91 (s, 2H), 2.23 (s, 3H), 2.10−2.00 (m, 1H), 1.04−0.94 (m,
2H), 0.94−0.83 (m, 2H) ppm. LC−MS (ESI) m/z calcd for
C16H17N5O [M + H]
+ 296.15, found 296.13. HPLC: 6.154 min,
purity 97%.
2-Amino-5-cyclopropyl-6-(3-fluorobenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (14). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (190 mg, 1.92 mmol, 1.45 equiv), 4bg
(350 mg, 1.32 mmol, 1.00 equiv), and BMIM-PF6 (1.14 mL, 5.54
mmol, 4.19 equiv). Yield: 15% (61 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 7.40−7.20 (m, 1H), 7.16−6.85 (m, 3H), 5.81
(br s, 2H), 4.01 (s, 2H), 2.12−1.95 (m, 1H), 1.10−0.85 (m, 4H)
ppm. LC−MS (ESI) m/z calcd for C15H14FN5O [M + H]+ 300.13,
found 300.1. HPLC: 5.812 min, purity 97%.
2-Amino-6-(3-bromobenzyl)-5-cyclopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (15). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (169 mg, 1.74 mmol, 2.00 equiv), 4bh
(283 mg, 0.87 mmol, 1.00 equiv), and BMIM-PF6 (1.07 mL, 5.22
mmol, 6.00 equiv). Yield: 43% (135 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.21 (br s, 1H), 7.43 (s, 1H), 7.34 (d, J = 7.2
Hz, 1H), 7.25 (d, J = 7.6 Hz, 1H), 7.20 (t, J = 7.6 Hz, 1H), 6.26 (br s,
2H), 3.96 (s, 2H), 2.12−2.04 (m, 1H), 1.04−0.94 (m, 2H), 0.94−
0.85 (m, 2H) ppm. LC−MS (ESI) m/z calcd for C15H14BrN5O [M +
H]+ 360.05, found 360.2. HPLC: 6.529 min, purity 99%.
2-Amino-5-cyclopropyl-6-(3-iodobenzyl)[1,2,4]triazolo[1,5-
a]pyrimidin-7(4H)-one (16). Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (190 mg, 1.92 mmol, 2.32 equiv), 4bi (320 mg, 0.86
mmol, 1.00 equiv), and BMIM-PF6 (1.14 mL, 4.25 mmol, 6.00
equiv). Yield: 26% (92 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.18 (br s, 1H), 7.62 (s, 4H), 7.51 (d, J = 7.6 Hz, 1H),
7.25 (d, J = 7.6 Hz, 1H), 7.05 (t, J = 7.6 Hz, 1H), 6.22 (br s, 2H),
3.92 (s, 2H), 2.12−2.07 (m, 1H), 1.01−0.94 (m, 2H), 0.93−0.86 (m,
2H). LC−MS (ESI) m/z calcd for C15H14IN5O [M + H]+ 408.03,
found 408.1. HPLC: 7.042 min, purity 96%.
2-Amino-5-cyclopropyl-6-(3-methoxybenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (17). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (146 mg, 1.50 mmol, 2.00 equiv), 4bj
(207 mg, 0.75 mmol, 1.00 equiv), BMIM-PF6 (0.93 mL, 4.50 mmol,
6.00 equiv). Yield: 21% (48 mg) as a white solid. 1H NMR (400
MHz, DMSO): δ 11.94 (br s, 1H), 7.15 (t, J = 8.0 Hz, 1H), 6.82−
6.77 (m, 2H), 6.72 (d, J = 7.6 Hz, 1H), 6.16 (br s, 2H), 3.93 (s, 2H),
3.69 (s, 3H), 2.11−2.03 (m, 1H), 1.04−0.96 (m, 2H), 0.96−0.85 (m,
2H) ppm. LC−MS (ESI) m/z calcd for C16H17N5O2 [M + H]+
312.15, found 312.13. HPLC: 5.675 min, purity 96%.
2-Amino-5-cyclopropyl-6-(3-(trifluoromethyl)benzyl)[1,2,4]-
triazolo[1,5-a]pyrimidin-7(4H)-one (18). Compound was synthe-
sized according to general procedure 3, using the following reagents:
3,5-diamino-4H-1,2,4-triazole 5c (150 mg, 1.54 mmol, 2.00 equiv),
4bk (242 mg, 0.77 mmol, 1.00 equiv), and BMIM-PF6 (0.95 mL, 4.62
mmol, 6.00 equiv). Yield 6% (17 mg) as a white solid. 1H NMR (400
MHz, DMSO): δ 12.18 (br s, 1H), 7.61 (s, 1H), 7.57−7.46 (m, 3H),
6.24 (br s, 2H), 4.06 (s, 2H), 2.17−2.08 (m, 1H), 1.03−0.95 (m,
2H), 0.94−0.86 (m, 2H) ppm. LC−MS (ESI) m/z calcd for
C16H14F3N5O [M + H]
+ 350.13, found 350.27. HPLC: 6.727 min,
purity 97%.
2-Amino-5-cyclopropyl-6-(4-methylbenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (19). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (197 mg, 2.03 mmol, 2.00 equiv), 4bl
(266 mg, 1.02 mmol, 1.00 equiv), and BMIM-PF6 (1.25 mL, 6.09
mmol, 6.00 equiv). Yield: 39% (115 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.06 (br s, 1H), 7.10 (d, J = 8.0 Hz, 2H),
7.03 (d, J = 8.0 Hz, 2H), 6.18 (br s, 2H), 3.90 (s, 2H), 2.23 (s, 3H),
2.08−2.01 (m, 1H), 1.01−0.94 (m, 2H), 0.94−0.87 (m, 2H) ppm.
LC−MS (ESI) m/z calcd for C16H17N5O [M + H]+ 296.15, found
296.13. HPLC: 6.279 min, purity 97%.
2-Amino-5-cyclopropyl-6-(4-fluorobenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (20). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (150 mg, 1.51 mmol, 2.00 equiv), 4bm
(200 mg, 0.756 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86
mmol, 6.39 equiv). Yield: 35% (79 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.13 (s, 1H), 7.28 (dd, J = 9.6, 2.4 Hz, 2H),
7.07 (t, J = 8.8 Hz, 2H), 6.21 (s br, 2H), 3.95 (s, 2H), 2.15−2.02 (m,
1H), 1.05−0.85 (m, 4H) ppm. LC−MS (ESI) m/z calcd for
C15H14FN5O [M + H]
+ 300.13, found 300.2. HPLC: 6.394 min,
purity 95%.
2-Amino-6-(4-chlorobenzyl)-5-cyclopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (21). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (179 mg, 1.84 mmol, 2.00 equiv), 4bn
(258 mg, 0.92 mmol, 1.00 equiv), and BMIM-PF6 (1.14 mL, 5.52
mmol, 6.00 equiv). Yield: 33% (105 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.18 (br s, 1H), 7.28 (d, J = 8.4 Hz, 2H),
7.25 (d, J = 8.4 Hz, 2H), 6.24 (br s, 2H), 3.94 (s, 2H), 2.10−2.00 (m,
1H), 1.04−0.94 (m, 2H), 0.93−0.81 (m, 2H) ppm. LC−MS (ESI)
m/z calcd for C15H14ClN5O [M + H]
+ 316.10, found 316.13. HPLC:
6.393 min, purity 96%.
2-Amino-5-cyclopropyl-6-(4-bromobenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (22). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (120 mg, 1.21 mmol, 2.00 equiv), 4bo
(200 mg, 0.615 mmol, 1.00 equiv), and BMIM-PF6 (1,00 mL, 4.86
mmol, 7.90 equiv). Yield: 21% (47 mg) as an off-white solid. 1H
NMR (400 MHz, DMSO): δ 12.15 (s, 1H), 7.42 (d, J = 8.4 Hz, 2H),
7.20 (d, J = 8.0 Hz, 2H), 6.24 (br s, 2H), 3.92 (s, 2H), 2.10−2.00 (m,
1H), 1.08−0.75 (m, 4H) ppm. LC−MS (ESI) m/z calcd for
C15H14BrN5O [M + H]
+ 360.05, found 360.1. HPLC: 6.474 min,
purity 96%.
2-Amino-5-cyclopropyl-6-(4-methoxybenzyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (23). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (165 mg, 1.70 mmol, 2.00 equiv), 4bp
(235 mg, 0.85 mmol, 1.00 equiv), and BMIM-PF6 (1.05 mL, 5.10
mmol, 6.00 equiv). Yield: 41% (109 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.07 (br s, 1H), 7.15 (d, J = 8.4 Hz, 2H),
6.80 (d, J = 8.8 Hz, 2H), 6.19 (br s, 2H), 3.88 (s, 2H), 3.69 (s, 3H),
2.12−2.01 (m, 1H), 1.04−0.95 (m, 2H), 0.94−0.86 (m, 2H) ppm.
LC−MS (ESI) m/z calcd for C16H17N5O2 [M + H]+ 312.15, found
312.07. HPLC: 5.753 min, purity 96%.
2-Amino-6-(3-chlorobenzyl)-5-methyl[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (24).23 Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (94 mg, 0.95 mmol, 2.00 equiv), 4aa (120 mg, 0.47
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mmol, 1.00 equiv), and BMIM-PF6 (0.58 mL, 2.82 mmol, 6.00
equiv). Yield: 57% (77 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.56 (s, 1H), 7.30−7.21 (m, 3H), 7.17 (d, J = 7.2 Hz,
1H), 5.99 (s, 2H), 3.78 (s, 2H), 2.25 (s, 3H) ppm. LC−MS (ESI) m/
z calcd for C13H12ClN5O [M + H]
+ 290.08, found 290.1. HPLC:
5.709 min, purity 99%.
2-Amino-6-(3-chlorobenzyl)-5-ethyl[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (25).23 Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (141 mg, 1.43 mmol, 2.00 equiv), 4ca (192 mg, 0.71
mmol, 1.00 equiv), and BMIM-PF6 (0.88 mL, 4.28 mmol, 6.00
equiv). Yield: 21% (46 mg) as a white solid. 1H NMR (500 MHz,
DMSO): δ 12.57 (s, 1H) 7.29−7.51 (m, 2H), 7.22 (d, J = 8.0 Hz,
1H), 7.16 (d, J = 7.5 Hz, 1H), 6.02 (s, 2H), 3.81 (s, 2H), 2.57 (q, J =
7.5 Hz, 2H), 1.05 (t, J= 7.5 Hz, 3H) ppm. LC−MS (ESI) m/z calcd
for C14H14ClN5O [M + H]
+ 304.10, found 304.2. HPLC: 6.156 min,
purity 95%.
2-Amino-6-(3-chlorobenzyl)-5-propyl[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (26).23 Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (210 mg, 2.12 mmol, 2.00 equiv), 4da (300 mg, 1.06
mmol, 1.00 equiv), and BMIM-PF6 (1.31 mL, 6.36 mmol, 6.00
equiv). Yield: 22% (76 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.56 (s, 1H), 7.29−7.20 (m, 3H), 7.16 (d, J = 7.6 Hz,
1H), 6.01 (s, 2H), 3.81 (s, 2H), 2.53 (t, J = 7.6 Hz, 2H), 1.45 (sextet,
J = 7.6 Hz, 2H), 0.85 (t, J = 7.2 Hz, 3H) ppm. LC−MS (ESI) m/z
calcd for C15H16ClN5O [M + H]
+ 318.11, found 318.2. HPLC: 6.660
min, purity 99%.
2-Amino-6-(3-chlorobenzyl)-5-isopropyl[1,2,4]triazolo[1,5-
a]pyrimidin-7(4H)-one (27).23 Compound was synthesized accord-
ing to general procedure 3, using the following reagents: 3,5-diamino-
4H-1,2,4-triazole 5c (284 mg, 2.87 mmol, 2.00 equiv), 1ea (407 mg,
1.44 mmol, 1.00 equiv), and BMIM-PF6 (1.76 mL, 8.63 mmol, 6.00
equiv). Yield: 21% (96 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.33 (s, 1H), 7.28 (t, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.21
(d, J = 8.0 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.04 (s, 2H) 3.89 (s,
2H), 3.18 (septet, J= 6.8 Hz, 1H), 1.12 (d, J= 6.8 Hz, 6H) ppm. LC−
MS (ESI) m/z calcd for C15H16ClN5O [M + H]
+ 318.11, found
318.2. HPLC: 6.596 min, purity 99%.
2-Amino-5-butyl-6-(3-chlorobenzyl)[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (28).23 Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (250 mg, 1.51 mmol, 2.14 equiv), 1fa (210 mg, 0.708
mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86 mmol, 6.86
equiv). Yield: 20% (47 mg) as a white solid. Purity: 98%. 1H NMR
(400 MHz, DMSO) δ 12.54 (s, 1H), 7.33−7.19 (m, 3H), 7.16 (d, J =
7.3 Hz, 1H), 6.02 (s, 2H), 3.82 (s, 2H), 2.60−2.50 (m, 2H), 1.45−
1.32 (m, 2H), 1.32−1.20 (m, 2H), 0.81 (t, J = 7.1 Hz, 3H) ppm. LC−
MS (ESI) m/z calcd for C16H18ClN5O [M + H]
+ 332.13, found
332.3. HPLC: 7.027 min, purity 98%.
2-Amino-6-(3-chlorobenzyl)-5-(2-ethylbutyl)[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (29). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (130 mg, 1.31 mmol, 2.13 equiv), 4ga
(200 mg, 0.616 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86
mmol, 7.89 equiv). Yield: 9% (20 mg) as a white solid. 1H NMR (400
MHz, DMSO): δ 12.49 (br s, 1H), 7.28 (t, J = 7.2 Hz, 1H), 7.24−
7.18 (m, 2H), 7.14 (d, J = 7.2 Hz, 1H), 5.91 (br s, 2H), 3.82 (s, 2H),
1.58 (s, 2H), 1.30−1.15 (m, 5H), 0.77 (t, J = 6.8 Hz, 6H) ppm. LC−
MS (ESI) m/z calcd for C18H22ClN5O [M + H]
+ 360.16, found
360.3. HPLC: 7.640 min, purity 97%.
2-Amino-6-(3-chlorobenzyl)-5-pentyl[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (30). Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (120 mg, 1.21 mmol, 1.88 equiv), 4ha (200 mg,
0.643 mmol; 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86 mmol, 7.56
equiv). Yield: 24% (52 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.43 (br s, 1H), 7.35−7.10 (m, 4H), 6.02 (br s, 2H),
3.82 (s, 2H), 1.45−1.15 (m, 6H), 0.79 (s, 3H) ppm. LC−MS (ESI)
m/z calcd for C17H20ClN5O [M + H]
+ 346.15, found 346.2. HPLC:
7.376 min, purity 98%.
2-Amino-6-(3-chlorobenzyl)-5-cyclopentyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (31). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (130 mg, 1.31 mmol, 2.00 equiv), 4ia
(200 mg, 0.647 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86
mmol, 7.51 equiv). Yield: 38% (86 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.36 (br s, 1H), 7.38−7.07 (m, 4H), 6.07 (br
s, 2H), 3.90 (s, 2H), 3.23 (m, 1H), 1.90−1.45 (m, 8H) ppm. LC−MS
(ESI) m/z calcd for C17H18ClN5O [M + H]
+ 344.13, found 344.1.
HPLC: 7.049 min, purity 99%.
2-Amino-6-(3-chlorobenzyl)-5-hexyl[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (32). Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (86 mg, 0.86 mmol, 2.00 equiv), 4ja (140 mg, 0.431
mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86 mmol, 11.3
equiv). Yield: 83% (128 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.50 (s, 1H), 7.33−7.19 (m, 3H), 7.15 (d, J = 6.8 Hz,
1H), 6.02 (s, 2H), 3.82 (s, 2H), 2.60−2.40 (m, 2H), 1.44−1.32 (m,
2H), 1.30−1.08 (m, 6H), 0.82 (t, J = 6.5 Hz, 3H) ppm. LC−MS
(ESI) m/z calcd for C18H22ClN5O [M + H]
+ 360.16, found 360.3.
HPLC: 7.843 min, purity 97%.
2-Amino-6-(3-chlorobenzyl)-5-heptyl[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (33). Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (116 mg, 1.18 mmol, 2.00 equiv), 4ka (200 mg,
0.591 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86 mmol, 8.22
equiv). Yield: 50% (108 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.55 (s, 1H), 7.30−7.19 (m, 3H), 7.15 (d, J = 6.4 Hz,
1H), 6.01 (s, 1H), 3.82 (s, 2H), 1.46−1.32 (m, 2H), 1.27−1.10 (m,
8H), 0.83 (t, J = 6.4 Hz, 3H) ppm. LC−MS (ESI) m/z calcd for
C19H24ClN5O [M + H]
+ 374.18, found 374.3. HPLC: 8.200 min,
purity 98%.
2-Amino-6-(3-chlorobenzyl)-5-phenyl[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (34). Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (177 mg, 1.79 mmol, 2.00 equiv), 4la (296 mg, 0.89
mmol, 1.00 equiv), and BMIM-PF6 (1.11 mL, 5.36 mmol, 6.00
equiv). Yield: 30% (95 mg) as a white solid. 1H NMR (500 MHz,
DMSO): δ 12.83 (s, 1H), 7.53−7.47 (m, 3H), 7.42 (dd, J = 8.0, 1.5
Hz, 2H), 7.20 (t, J = 8.0 Hz, 1H), 7.17 (d, J = 7.0 Hz, 1H), 7.03 (s,
1H), 6.94 (d, J = 7.0 Hz, 1H), 6.12 (s, 2H), 3.64 (s, 2H) ppm. LC−
MS (ESI) m/z calcd for C18H14ClN5O [M + H]
+ 352.10, found
352.2. HPLC: 6.946 min, purity 99%.
2-Amino-6-(3-chlorobenzyl)-5-(p-tolyl)[1,2,4]triazolo[1,5-a]-
pyrimidin-7(4H)-one (35). Compound was synthesized according
to general procedure 3, using the following reagents: 3,5-diamino-4H-
1,2,4-triazole 5c (181 mg, 1.82 mmol, 2.00 equiv), 4ma (314 mg,
0.937 mmol, 1.00 equiv), and BMIM-PF6 (1.5 mL, 7.28 mmol, 7.77
equiv). Yield: 33% (108 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.80 (s, 1H), 7.33−7.28 (m, 4H), 7.26−7.14 (m, 2H),
7.05 (s, 1H), 6.96 (d, J = 7.1 Hz, 1H), 6.11 (s, 2H), 3.64 (s, 2H), 2.36
(s, 3H) ppm. LC−MS (ESI) m/z calcd for C19H16ClN5O [M + H]+
366.20, found 366.2. HPLC: 7.342 min, purity 98%.
Procedure for the synthesis of 2-Amino-6-(3-chlorobenzyl)-
5-phenethyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one (36). A
mixture of 4na (213 mg, 0.57 mmol, 1.00 equiv), 3,5-diamino-4H-
1,2,4-triazole 5c (116 mg, 1.16 mmol, 2.00 equiv), and ortho-
phosphoric acid 85% (59.6 μL, 0.906 mmol,1.58 equiv) in EtOH (1
mL) was stirred for 1 min at 20 °C and then heated at 175 °C under
microwave irradiation for 3 h. The reaction mixture was allowed to
cool to room temperature, and CH2Cl2 (30 mL), water (10 mL), and
aqueous citric acid (5%, 1 mL) were added. The resulting precipitate
was stirred for 20 min, filtered, and the residue was washed with hot
methanol, collected, and dried in vacuo to afford the title compound.
Yield: 22% (49 mg) as a white solid. 1H NMR (400 MHz, DMSO): δ
12.67 (s, 1H), 7.32−7.18 (m, 6H), 7.17−7.10 (m, 3H), 6.06 (br s,
2H), 3.76 (s, 2H), 2.84−2.78 (m, 2H), 2.70−2.66 (m, 2H) ppm.
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LC−MS (ESI) m/z calcd for C20H18ClN5O [M + H]+ 380.13, found
380.2. HPLC: 7.392 min, purity 97%.
2-Amino-5-cyclopropyl-6-(3,4-dichlorobenzyl)[1,2,4]-
triazolo[1,5-a]pyrimidin-7(4H)-one (37).23 Compound was syn-
thesized according to general procedure 3, using the following
reagents: 3,5-diamino-4H-1,2,4-triazole 5c (157 mg, 1.58 mmol, 2.00
equiv), 4bq (250 mg, 0.79 mmol, 1.00 equiv), and BMIM-PF6 (1.3
mL, 4.74 mmol, 6.00 equiv). Yield: 31% (86 mg) as a white solid. 1H
NMR (400 MHz, DMSO): δ 12.26 (br s, 1H), 7.52−7.47 (m, 2H),
7.22 (d, J = 8.4 Hz, 2H), 6.26 (br s, 2H), 3.95 (s, 2H), 2.12−2.01 (m,
1H), 1.01−0.85 (m, 4H) ppm. LC−MS (ESI) m/z calcd for
C15H13Cl2N5O [M + H]
+ 350.06, found 350.1. HPLC: 6.836 min,
purity 96%.
2-Amino-6-(3,4-dichlorobenzyl)-5-isopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (38). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (125 mg, 1.26 mmol, 2.00 equiv), 4eq
(200 mg, 0.63 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86
mmol, 7.71 equiv). Yield: 34% (76 mg), as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.23 (br s, 1H), 7.54−7.43 (m, 2H), 7.17 (d,
J = 8.0 Hz, 1H), 6.09 (s, 2H), 3.88 (s, 2H), 3.22−3.13 (m, 1H), 1.12
(d, J = 6.4 Hz, 6H) ppm. LC−MS (ESI) m/z calcd for C15H15Cl2N5O
[M + H]+ 352.08, found 352.3. HPLC: 7.008 min, purity 97%.
2-Amino-6-(2,3-dichlorobenzyl)-5-isopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (39). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (125 mg, 1.26 mmol, 2.00 equiv), 4er
(200 mg, 0.630 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86
mmol, 7.71 equiv). Yield: 48% (106 mg) as a white solid. 1H NMR
(500 MHz, DMSO-d6, 80 °C): δ 7.44 (dd, J = 7.9, 1.5 Hz, 1H), 7.21
(t, J = 7.9 Hz, 1H), 6.97 (dd, J = 7.2, 1.5 Hz, 1H), 5.83 (s br, 2H),
3.98 (s, 2H), 2.96 (pentet, J = 6.9 Hz, 1H), 1.16 (d, J = 6.9 Hz, 6H)
ppm. 13C NMR (126 MHz, DMSO-d6): δ 161.8, 156.0, 155.6, 149.7,
140.1, 131.4, 130.5, 127.7, 127.4, 126.9, 104.5, 29.4, 28.3, 19.6 ppm.
LC−MS (ESI) m/z calcd for C15H15Cl2N5O [M + H]+ 352.08, found
352.2. HPLC: 7.060 min, purity 97%.
2-Amino-6-(2,5-dichlorobenzyl)-5-isopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (40). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (125 mg, 1.26 mmol, 2.00 equiv), 4es
(200 mg, 0.630 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86
mmol, 7.71 equiv). Yield: 24% (54 mg) as a white solid. 1H NMR
(400 MHz, DMSO): δ 12.41 (br s, 1H), 7.70−7.42 (m, 1H), 7.40−
7.19 (m, 1H), 7.16−6.85 (m, 1H), 6.08 (br s, 2H), 3.88 (s, 2H),
3.01−2.83 (m, 1H), 1.14 (s, 6H) ppm. LC−MS (ESI) m/z calcd for
C15H15Cl2N5O [M + H]
+ 352.08, found 352.2. HPLC: 6.938 min,
purity 96%.
2-Amino-6-(3,5-dichlorobenzyl)-5-isopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin-7(4H)-one (41). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (96 mg, 0.97 mmol, 2 equiv), 4et (153
mg, 0.48 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86 mmol,
10 equiv). Yield: 18% (31 mg) as a white solid. 1H NMR (400 MHz,
DMSO): δ 12.33 (s, 1H), 7.41 (s, 1H), 7.26 (s, 2H), 6.07 (br s, 2H),
3.89 (s, 2H), 1.13 (s, 6H) ppm. LC−MS (ESI) m/z calcd for
C15H15Cl2N5O [M + H]
+ 352.08, found 352.1. HPLC: 7.103 min,
purity 98%.
2-Amino-6-(3,5-dibromobenzyl)-5-isopropyl[1,2,4]triazolo-
[1,5-a]pyrimidin 7(4H)-one (42). Compound was synthesized
according to general procedure 3, using the following reagents: 3,5-
diamino-4H-1,2,4-triazole 5c (97 mg, 0.98 mmol, 2.00 equiv), 4eu
(200 mg, 0.49 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL, 4.86
mmol, 9.91 equiv). Yield: 7% (14 mg) as a white solid. 1H NMR (400
MHz, DMSO): δ 12.33 (br s, 1H), 7.63 (s, 1H), 7.42 (s, 2H), 6.07
(br s, 2H), 3.88 (s, 2H), 1.13 (s, 6H) ppm. LC−MS (ESI) m/z calcd
for C15H15Br2N5O [M + H]
+ 439.97, found 440.1. HPLC: 7.337 min,
purity 98%.
2-Amino-6-(3-bromo-4-chloro-benzyl)-5-isopropyl[1,2,4]-
triazolo[1,5-a]pyrimidin-7(4H)-one (43). Compound was synthe-
sized according to general procedure 3, using the following reagents:
3,5-diamino-4H-1,2,4-triazole 5c (109 mg, 1.10 mmol, 2.00 equiv),
4ev (200 mg, 0.553 mmol, 1.00 equiv), and BMIM-PF6 (1.00 mL,
4.86 mmol, 8.83 equiv). Yield: 24% (53 mg) as a white solid. 1H
NMR (400 MHz, DMSO): δ 7.60 (d, J = 2.0 Hz, 1H), 7.49 (d, J = 8.0
Hz, 1H), 7.21 (dd, J = 8.0, 2.0 Hz, 1H), 6.08 (br s, 2H), 3.87 (s, 2H),
3.22−3.11 (m, 1H), 1.12 (d, J = 7.2 Hz, 6H) ppm. LC−MS (ESI) m/
z calcd for C15H15BrClN5O [M + H]
+ 396.02, found 396.1. HPLC:
7.080 min, purity 98%.
Chemicals and Reagents. The human recombinant chemokines
CCL2 and CCL3 were purchased from PeproTech (Rocky Hill, NJ).
TAK-779 was obtained from NIH AIDS reagent program (German-
town, MD, catalogue number 4983). All triazolopyrimidinone
derivatives were synthesized in-house. Guanosine 5′-O-[γ-thio]-
triphosphate ([35S[GTPγS) (specific activity 1250 Ci/mmol) was
purchased from PerkinElmer (Waltham, MA), while [3H]-CCR2-RA-
[R] (specific activity 59.6 Ci mmol−1) was custom-labeled by Vitrax
(Placentia, CA). Bovine serum albumin was purchased from Sigma-
Aldrich (St. Louis, MO). Bicinchoninic acid (BCA) and Pierce BCA
protein assay kit were purchased from Pierce Biotechnology (Thermo
Scientific, Rockford, IL). Tango U2OS cells stably expressing human
CCR2b (U2OS-CCR2) or human CCR5 (U2OS-CCR5) were
purchased from Invitrogen (Carlsbad, CA). All other chemicals
were obtained from standard commercial sources.
Cell Culture. Both U2OS-CCR2b and U2OS-CCR5 cells were
cultured in McCoy’s 5A medium supplemented with 10% (v/v) fetal
calf serum, 2 mM glutamine, 0.1 mM nonessential amino acids, 25
mM HEPES, 1 mM sodium pyruvate, 200 IU/mL penicillin, 200 μg/
mL streptomycin, 100 μg/mL G418, 40−50 μg/mL hygromycin, and
125 μg/mL zeocin. Cells were grown until 80% confluence and
cultured twice-weekly on 10 or 15 cm ⌀ plates by trypsinization.
Dialyzed fetal calf serum was used when culturing cells for functional
assays or as a last step before membrane preparation.
Membrane Preparation. Membranes from U2OS-CCR2 or
U2OS-CCR5 cells were prepared as previously described for CCR2.20
Briefly, U2OS-CCR2 or U2OS-CCR5 cells were scraped from
confluent 15 cm ⌀ plates using phosphate buffered saline (PBS)
and subsequently centrifuged at 3000 rpm for 5 min. Pellets were then
resuspended in ice-cold Tris buffer (50 mM Tris-HCl, 5 mM MgCl2,
pH 7.4) before homogenization with an Ultra Turrax homogenizer
(IKA-Werke GmbH & Co. KG, Staufen, Germany). Membranes and
cytosolic contents were separated using an Optima LE-80 K
ultracentrifuge (Beckman Coulter, Inc., Fullerton, CA) at 31 000
rpm for 20 min at 4 °C. After a second cycle of homogenization and
centrifugation, the final pellet was resuspended and homogenized in
ice-cold Tris buffer, aliquoted, and stored at −80 °C. Finally,
membrane protein concentrations were determined using a BCA
protein determination assay, as described by the manufacturer (Pierce
BCA protein assay kit).53
[3H]-CCR2-RA-[R] Binding Assays. For [3H]-CCR2-RA-[R]
displacement assays, U2OS-CCR2b membrane homogenates (15−
20 μg of total protein) were incubated with ∼6 nM [3H]-CCR2-RA-
[R] and at least 6 increasing concentrations of competing ligand in a
final volume of 100 μL of assay buffer (50 mM Tris-HCl, 5 mM
MgCl2, 0.1% CHAPS, pH 7.4). Ligands were diluted to the desired
concentration with an HP D300 digital dispenser (Tecan, Giessen,
The Netherlands). Total radioligand binding did not exceed 10% of
the amount added to prevent ligand depletion, and nonspecific
binding was determined using 10 μM CCR2-RA-[R]. After 2 h at 25
°C, incubation was terminated by rapid filtration through a 96-well
GF/B filterplate on a PerkinElmer FilterMate harvester, using ice-cold
wash buffer (50 mM Tris-HCl buffer supplemented with 5 mM
MgCl2 and 0.05% CHAPS, pH 7.4). Filters were washed 10 times
with ice-cold wash buffer and subsequently dried at 55 °C for 30 min.
After addition of 25 μL of Microscint scintillation cocktail
(PerkinElmer), the filter-bound radioactivity was measured by
scintillation spectrometry using the P-E 2450 Microbeta2 counter
(PerkinElmer).
Tango β-Arrestin Recruitment Assay. β-Arrestin recruitment
was measured using the Tango CCR2-bla or CCR5-bla U2OS cell-
based assay (Invitrogen) according to the manufacturer’s protocol.
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Briefly, U2OS-CCR2b or U2OS-CCR5 cells were grown until
approximately 80% confluence and detached by trypsinization. Cells
were recovered by centrifugation at 1000 rpm for 5 min, resuspended
in assay medium (FreeStyle Expression Medium, Invitrogen) to a
density of 10 000 cells per well and seeded into black-wall, clear-
bottom, 384-well assay plates (Corning). For agonist assays, cells were
exposed to increasing concentrations of CCL2 or CCL3 for CCR2 or
CCR5, respectively, for 16 h at 37 °C and 5% CO2. For antagonist
assays, compounds were first diluted in assay medium containing a
final DMSO concentration of 0.5% or lower. Cells were then
preincubated with either 1 μM (for single-point inhibition experi-
ments) or increasing concentrations of antagonist for 30 min at room
temperature, before a 16 hour co-incubation with an EC80
concentration of CCL2 (5 nM) or CCL3 (14 nM) at 37 °C and
5% CO2. After 16 h cells were loaded in the dark with 8 μL of
LiveBLAzer-FRET B/G substrate (Invitrogen) and incubated for 2 h
at room temperature. Finally, fluorescence emission at 460 and 535
nm was measured in an EnVision multilabel plate reader
(PerkinElmer) after excitation at 400 nm. The ratio of emission at
460 and 535 nm was calculated for each well.
[35S]GTPγS Binding Assay. To determine the mechanism of
inhibition [35S]GTPγS binding assays were performed. In CCR2 the
[35S]GTPγS binding assay was performed as previously described.19,20
In the case of CCR5, an amount of 10 μg of U2OS-CCR5 membranes
with 0.25 mg/mL saponin was preincubated with 5 μM GDP,
increasing concentrations of CCL3, and three different antagonist
concentrations for 30 min at 25 °C. All dilutions were made in assay
buffer containing 50 mM Tris-HCl (pH 7.4), 10 mM MgCl2, 10 mM
NaCl, 1 mM EDTA, and 0.05% BSA. [35S]GTPγS (0.3 nM) was
added, and the mixture was co-incubated for an additional 90 min at
25 °C before harvesting. Incubation was stopped by dilution with ice-
cold 50 mM Tris-HCl buffer with 5 mM MgCl2. Separation of bound
and unbound radioligand was performed by rapid filtration through a
96-well GF/B filter plate as described in “[3H]-CCR2-RA-[R] Binding
Assays”.
Data Analysis. All experiments were analyzed using nonlinear
regression curve fitting program Prism 7 (GraphPad, San Diego, CA).
EC50, EC80, Emax, and IC50 values from functional assays were
obtained by nonlinear regression analysis. All values obtained are the
mean ± SEM of at least three separate experiments performed in
duplicate, unless stated otherwise. For radioligand binding assays, Ki
values were determined using the Cheng−Prussoff equation using a
KD of 6.3 nM for the radioligand.
19
Computational Modeling. The inactive crystal structure of
hCCR2b with BMS-681 and CCR2-RA-[R] (PDB code 5T1A)15 was
used as the basis for docking compounds 8, 39, 40, and 43. Docking
was performed in the Schrodinger suite,54 as previously described for
the docking of CCR2-RA-[R].19 Before docking, the CCR2b crystal
structure was prepared by replacing the residues between L2265×62
and R2406×32, which correspond to the M2 muscarinic acetylcholine
receptor, with the CCR2b sequence using prime55−57 and CCR5 as
template (PDB code 4MBS).35 Induced fit docking, with a
substructure restraint on the right-hand phenyl (R1, SMARTS:
“c1ccccc1”) was used to dock compound 43 in the hCCR2b
model.58,59 Compounds 8, 39, and 40 were docked using regular
docking (Glide-SP) on the basis of the model of compound 43.
Figures 4a, 4b, and S4 were rendered using PyMOL.60
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